|
18 Feb 2019
|
FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
|
|
18 Feb 2019
|
FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
|
|
04 Feb 2019
|
Genentech Submits Supplemental Biologics License Application to FDA For Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
29 Jan 2019
|
Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue
|
|
16 Jan 2019
|
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
|
06 Dec 2018
|
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
|
|
05 Dec 2018
|
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
04 Dec 2018
|
FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer
|
|
03 Dec 2018
|
Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors
|
|
03 Dec 2018
|
New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia
|
|
26 Nov 2018
|
FDA Approves The ACTpen For Genentech’s ACTEMRA, A Single-Dose, Prefilled Autoinjector For The Treatment Of Rheumatoid Arthritis, Giant Cell Arteritis And Two Forms Of Juvenile Arthritis
|
|
21 Nov 2018
|
Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy
|
|
12 Nov 2018
|
FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
|
|
01 Nov 2018
|
Genentech to Present New Data From Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
|
|
31 Oct 2018
|
Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
|
|
27 Oct 2018
|
New STAIRWAY Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)
|
|
24 Oct 2018
|
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
|
|
22 Oct 2018
|
Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
|
|
21 Oct 2018
|
Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People With NTRK Fusion-Positive Solid Tumors
|
|
20 Oct 2018
|
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
|
|
19 Oct 2018
|
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
|
|
14 Oct 2018
|
Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
09 Oct 2018
|
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
|
|
08 Oct 2018
|
Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and Across a Wide Range of Cancers at The European Society for Medical Oncology (ESMO) 2018 Congress
|
|
04 Oct 2018
|
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
|
|
03 Oct 2018
|
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
|
|
03 Oct 2018
|
Positive Phase III Results for Baloxavir Marboxil in People at High Risk of Complications From Influenza to be Presented at IDWeek 2018
|
|
01 Oct 2018
|
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
|
|
28 Sep 2018
|
FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation
|
|
25 Sep 2018
|
Genentech’s TECENTRIQ in Combination With Chemotherapy Helped People Live Significantly Longer as an Initial Treatment for People With Extensive-Stage Small Cell Lung Cancer
|
|
24 Sep 2018
|
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer
|
|
24 Sep 2018
|
Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer
|
|
13 Sep 2018
|
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
|
|
05 Sep 2018
|
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
|
|
29 Aug 2018
|
Positive Phase III Results for Genentech’s HEMLIBRA® (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
|
|
12 Aug 2018
|
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
|
|
25 Jul 2018
|
Genentech Unveils Positive Phase II Results for the Port Delivery System with Ranibizumab (PDS), the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
|
|
19 Jul 2018
|
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)
|
|
18 Jul 2018
|
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
|
|
17 Jul 2018
|
FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
|
16 Jul 2018
|
Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
|
|
11 Jul 2018
|
Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
|
|
01 Jul 2018
|
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
|
|
25 Jun 2018
|
FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza
|
|
24 Jun 2018
|
Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
|
|
13 Jun 2018
|
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
|
|
13 Jun 2018
|
Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
|
|
08 Jun 2018
|
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
|
|
07 Jun 2018
|
FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
|
|
04 Jun 2018
|
FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
|
|
02 Jun 2018
|
Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer
|
|
28 May 2018
|
Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
|
|
20 May 2018
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
|
|
16 May 2018
|
Follow-Up Phase III Data Showed Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
|
|
16 May 2018
|
Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
|
|
14 May 2018
|
FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
|
|
13 May 2018
|
Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
|
|
09 May 2018
|
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
|
|
07 May 2018
|
Genentech to Present New Data From Its Industry-Leading Oncology Portfolio at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
06 May 2018
|
FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
|
|
22 Apr 2018
|
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
|
|
16 Apr 2018
|
FDA Grants Breakthrough Therapy Designation For Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia A Without Inhibitors
|
|
15 Apr 2018
|
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
|
|
25 Mar 2018
|
Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel
|
|
21 Mar 2018
|
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
|
|
19 Mar 2018
|
Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer
|
|
13 Feb 2018
|
FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
|
|
11 Feb 2018
|
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
|
|
05 Feb 2018
|
Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer
|
|
20 Dec 2017
|
FDA Approves Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
|
|
12 Dec 2017
|
Genentech Announces Phase III Data Showing Venclexta plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia
|
|
10 Dec 2017
|
Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
|
|
10 Dec 2017
|
Phase III IMmotion151 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
|
|
09 Dec 2017
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People with Hemophilia A with Inhibitors
|
|
06 Dec 2017
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
|
|
06 Dec 2017
|
Phase III IMpower150 Study Showed Tecentriq (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Reduced the Risk of Disease Worsening or Death by 38 Percent for People with a Type of Advanced Lung Cancer
|
|
05 Dec 2017
|
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
|
|
04 Dec 2017
|
First “Cancer Screen Week” Calls on Americans to Act Now Against Cancer by Taking Pledge to Get Screened
|
|
19 Nov 2017
|
Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
|
|
19 Nov 2017
|
Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
|
|
16 Nov 2017
|
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
|
|
16 Nov 2017
|
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
|
|
06 Nov 2017
|
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
|
|
06 Nov 2017
|
FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
|
|
01 Nov 2017
|
Genentech to Present New Data Across a Range of Blood Diseases at The American Society of Hematology (ASH) 2017 Annual Meeting
|
|
26 Oct 2017
|
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
|
|
25 Oct 2017
|
FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer
|
|
15 Oct 2017
|
Genentech to Present New Ocrevus (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS
|
|
28 Sep 2017
|
FDA Grants Priority Review for Genentech’s Perjeta® (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
|
|
18 Sep 2017
|
Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared to Bendamustine Plus Rituxan
|
|
08 Sep 2017
|
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
|
|
06 Sep 2017
|
Genentech Issues Voluntary Nationwide Recall of Three Lots of Activase® (Alteplase)-100 mg Due to Lack of Sterility Assurance of the Sterile Water for Injection
|
|
30 Aug 2017
|
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
|
|
27 Aug 2017
|
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
|
|
23 Aug 2017
|
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
|
|
07 Aug 2017
|
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
|
|
02 Aug 2017
|
FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
|
|
26 Jul 2017
|
Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine
|
|
10 Jul 2017
|
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
|
|
25 Jun 2017
|
Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
|
|
22 Jun 2017
|
FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
|
|
22 Jun 2017
|
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
|
|
05 Jun 2017
|
APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer
|
|
05 Jun 2017
|
Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
|
|
22 May 2017
|
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
|
|
10 May 2017
|
Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
09 May 2017
|
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
|
|
25 Apr 2017
|
New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
|
|
18 Apr 2017
|
Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two Types of Multiple Sclerosis
|
|
17 Apr 2017
|
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
|
|
17 Apr 2017
|
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
|
|
16 Apr 2017
|
Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
|
|
09 Apr 2017
|
Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer
|
|
29 Mar 2017
|
FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
|
|
28 Mar 2017
|
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
|
|
23 Mar 2017
|
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
|
|
01 Mar 2017
|
Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy
|
|
17 Feb 2017
|
Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma
|
|
23 Jan 2017
|
FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis
|
|
08 Jan 2017
|
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
|
|
05 Jan 2017
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
|
|
21 Dec 2016
|
Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journal of Medicine
|
|
21 Dec 2016
|
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
|
|
20 Dec 2016
|
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
|
|
06 Dec 2016
|
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
|
|
04 Dec 2016
|
Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer without their Disease Worsening Compared to Rituxan
|
|
12 Nov 2016
|
Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis
|
|
03 Nov 2016
|
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
|
|
01 Nov 2016
|
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
|
|
18 Oct 2016
|
FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
|
|
14 Oct 2016
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
|
|
10 Oct 2016
|
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
|
|
08 Oct 2016
|
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III Study
|
|
04 Oct 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
|
|
03 Oct 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
|
|
13 Sep 2016
|
Phase III Efficacy Results of Investigational Medicine Ocrevus™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
|
|
31 Aug 2016
|
Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy
|
|
17 Jul 2016
|
Genentech Provides Update on Phase III Study of Gazyva® in People with Previously Untreated Diffuse Large B-Cell Lymphoma
|
|
07 Jul 2016
|
FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma in Children
|
|
27 Jun 2016
|
FDA Grants Priority Review for Genentech’s OCREVUS™ (Ocrelizumab) Biologics License Application
|
|
05 Jun 2016
|
Genentech’s Cancer Immunotherapy Tecentriq™ (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
|
|
05 Jun 2016
|
Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis (GCA)
|
|
26 May 2016
|
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
|
|
18 May 2016
|
FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer
|
|
18 May 2016
|
Phase III Study of Genentech’s Alecensa® (alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People with a Specific Type of Lung Cancer
|
|
02 May 2016
|
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
12 Apr 2016
|
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
|
|
11 Apr 2016
|
Genentech Announces FDA Grants Venclexta™ (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
|
|
10 Apr 2016
|
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
|
|
14 Mar 2016
|
FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
|
|
01 Mar 2016
|
FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Pediatric Allergic Asthma
|
|
28 Feb 2016
|
Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma
|
|
26 Feb 2016
|
FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
|
|
16 Feb 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
|
|
12 Jan 2016
|
FDA Grants Priority Review for Venetoclax New Drug Application
|
|
11 Dec 2015
|
FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
|
|
06 Dec 2015
|
Pivotal Phase II Study Showed Nearly 80 Percent of People with Hard-to-treat Type of Chronic Lymphocytic Leukemia Responded to Investigational Medicine Venetoclax
|
|
05 Dec 2015
|
New Results from CLL11 Study Show Gazyva® Provided People with Previously Untreated Chronic Lymphocytic Leukemia a Treatment-free Period of Nearly Four Years
|
|
21 Nov 2015
|
Updated Data Showed That Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) Helped People With a Specific Type of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone
|
|
10 Nov 2015
|
FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma
|
|
05 Nov 2015
|
Genentech to Present New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2015 Annual Meeting
|
|
08 Oct 2015
|
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
|
|
27 Sep 2015
|
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
|
|
26 Sep 2015
|
Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer at 2015 European Cancer Congress
|
|
26 Sep 2015
|
Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Presented at 2015 European Cancer Congress
|
|
08 Sep 2015
|
FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
|
|
07 Sep 2015
|
Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress
|
|
03 Sep 2015
|
U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
|
|
16 Aug 2015
|
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
|
|
12 Aug 2015
|
Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
|
|
12 Jul 2015
|
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
|
|
29 Jun 2015
|
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
|
|
10 Jun 2015
|
FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis
|
|
31 May 2015
|
Genentech’s Perjeta Regimen Helped People with HER2-Positive Early Breast Cancer Live Longer without Their Disease Returning or Getting Worse Compared to Herceptin and Chemotherapy
|
|
30 May 2015
|
Genentech’s Gazyva® Extended the Time People with Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening
|
|
30 May 2015
|
Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening
|
|
13 May 2015
|
Genentech’s Investigational Immunotherapy MPDL3280A Reduced the Risk of Death by Half Compared with Chemotherapy in People with a Specific Type of Lung Cancer
|
|
13 May 2015
|
Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer
|
|
10 May 2015
|
Pivotal Data for Genentech Medicines in Lung and Blood Cancers To Be Presented at ASCO
|
|
04 May 2015
|
Genentech Announces New STEM Education Initiative to Support South San Francisco Schools
|
|
26 Mar 2015
|
Genentech Announces Plans To Expand Hillsboro Facility
|
|
18 Feb 2015
|
FDA Grants Genentech's Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
|
|
06 Feb 2015
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema
|
|
03 Feb 2015
|
Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
|
|
01 Feb 2015
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) in Non-Small Cell Lung Cancer
|
|
24 Dec 2014
|
FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia
|
|
18 Dec 2014
|
Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer
|
|
14 Dec 2014
|
Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination with Zelboraf (vemurafenib) in Advanced Melanoma
|
|
05 Dec 2014
|
Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting
|
|
14 Nov 2014
|
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer
|
|
15 Oct 2014
|
FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
|
|
08 Oct 2014
|
FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Retinopathy
|
|
29 Sep 2014
|
Genentech’s Investigational Combination of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit to People With Advanced Melanoma Over Zelboraf Alone
|
|
28 Sep 2014
|
Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer By 15.7 Months Compared to Herceptin and Chemotherapy
|
|
14 Aug 2014
|
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
|
|
08 Aug 2014
|
Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
|
|
21 Jul 2014
|
FDA Grants Genentech’s Avastin Priority Review For Recurrent Platinum-resistant Ovarian Cancer
|
|
14 Jul 2014
|
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
|
|
13 Jul 2014
|
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer without their Disease Worsening
|
|
01 Jul 2014
|
Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
|
|
31 May 2014
|
Investigational Immunotherapy Anti-PDL1 (MPDL3280A) Shrank Tumors in 43 Percent of People With a Specific Type of Metastatic Bladder Cancer in a Genentech Study
|
|
13 May 2014
|
Genentech to Present New Data on 27 Different Medicines at ASCO
|
|
21 Mar 2014
|
FDA Approves Xolair® (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
|
|
02 Mar 2014
|
Genentech Provides Update On Phase III Study Of Onartuzumab in People With Specific Type of Lung Cancer
|
|
07 Nov 2013
|
Genentech’s Gazyva Helped People with One of the Most Common Forms of Blood Cancer Live Significantly Longer without Their Disease Worsening Compared to Rituxan in Phase III CLL11 Study
|
|
01 Nov 2013
|
FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
|
|
21 Oct 2013
|
Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
|
|
13 Oct 2013
|
Genentech Announces Plans to Expand California Biologics Manufacturing Facilities
|
|
10 Oct 2013
|
FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)
|
|
30 Sep 2013
|
FDA Grants Genentech’s Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Breast Cancer
|
|
27 Sep 2013
|
Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New Phase III Study
|
|
12 Sep 2013
|
FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer
|
|
09 Sep 2013
|
Genentech Executive Vice President Wins Lasker Award
|
|
23 Jul 2013
|
Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer Than Rituxan® in People with One of the Most Common Forms of Blood Cancer
|
|
02 Jul 2013
|
FDA Grants Genentech's Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
|
|
01 Jul 2013
|
FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
|
|
02 Jun 2013
|
Genentech's Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Chemotherapy Alone
|
|
01 Jun 2013
|
Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer
|
|
15 May 2013
|
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
|
|
14 May 2013
|
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
|
|
14 May 2013
|
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
|
|
30 Apr 2013
|
FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis
|
|
24 Feb 2013
|
Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic form of Hives who Failed Standard Therapy
|
|
22 Feb 2013
|
FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer
|
|
30 Jan 2013
|
Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)
|
|
23 Jan 2013
|
FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
|
|
21 Dec 2012
|
Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants
|
|
07 Dec 2012
|
Genentech's Perjeta Significantly Extends Survival in People With HER2-Positive Metastatic Breast Cancer
|
|
17 Nov 2012
|
Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Worsening When Added to Radiation and Chemotherapy
|
|
10 Nov 2012
|
ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy
|
|
06 Nov 2012
|
FDA Grants Genentech's Trastuzumab Emtansine (T-DM1) Priority Review for HER2-Positive Metastatic Breast Cancer
|
|
12 Oct 2012
|
FDA Approves Expanded Indication for ACTEMRA® in Rheumatoid Arthritis
|
|
01 Oct 2012
|
Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
|
|
26 Aug 2012
|
New Data from Phase III EMILIA Study Showed Genentech's Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast Cancer
|
|
10 Aug 2012
|
FDA Approves Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)
|
|
09 Aug 2012
|
Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
|
|
26 Jul 2012
|
Genentech Reports Second Positive Study of ACTEMRA® Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
|
|
26 Jul 2012
|
FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
|
|
21 Jun 2012
|
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech's Perjeta
|
|
08 Jun 2012
|
FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
|
|
05 Jun 2012
|
Genentech's ACTEMRA® Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab as Single-Agent Therapy
|
|
02 Jun 2012
|
Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial
|
|
02 Jun 2012
|
Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy
|
|
01 Jun 2012
|
Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by Half
|
|
15 May 2012
|
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
|
|
02 May 2012
|
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
|
|
29 Mar 2012
|
Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
|
|
01 Mar 2012
|
Genentech's ACTEMRA® Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
|
|
07 Feb 2012
|
FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
|
|
30 Jan 2012
|
FDA Approves Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma
|
|
13 Jan 2012
|
Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
|
|
07 Dec 2011
|
Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer
|
|
29 Nov 2011
|
Genentech to Present Important New Data for HER2-Positive Breast Cancer at 2011 San Antonio Breast Cancer Symposium
|
|
18 Nov 2011
|
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
|
|
08 Nov 2011
|
FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
|
|
05 Nov 2011
|
Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
|
|
19 Oct 2011
|
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
|
|
24 Sep 2011
|
Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care in HER2-Positive Metastatic Breast Cancer
|
|
12 Sep 2011
|
Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
|
|
17 Aug 2011
|
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
|
|
14 Jul 2011
|
Pertuzumab Combined with Herceptin and Chemotherapy Significantly Extended the Time People with
HER2-Positive Metastatic Breast Cancer Lived without Their Disease Getting Worse
|
|
29 Jun 2011
|
Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer
|
|
28 Jun 2011
|
Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy
|
|
19 Jun 2011
|
Pivotal Study Showed Vismodegib Helped Shrink Tumors or Heal Lesions in People with Rare Form of Advanced Skin Cancer
|
|
05 Jun 2011
|
Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations
|
|
04 Jun 2011
|
Genentech Announces Data to Show Avastin-Based Regimen Halved the Risk of Disease Getting Worse in Women with Recurrent Ovarian Cancer
|
|
02 Jun 2011
|
Tarceva Nearly Doubled the Time People with a Genetically Distinct Type of Lung Cancer Lived without Their Disease Getting Worse
|
|
18 May 2011
|
MetMAb in Combination with Tarceva Doubled the Time People with Lung Cancer Lived without Their Disease Getting Worse
|
|
17 May 2011
|
Genentech to Present Significant Progress in Advanced Skin, Lung and Ovarian Cancers at ASCO
|
|
10 May 2011
|
New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer
|
|
19 Apr 2011
|
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
|
|
15 Apr 2011
|
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
|
|
25 Mar 2011
|
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
|
|
20 Mar 2011
|
Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
|
|
10 Mar 2011
|
Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular Edema
|
|
24 Feb 2011
|
FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer in the United States
|
|
11 Feb 2011
|
Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)
|
|
07 Feb 2011
|
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
|
|
28 Jan 2011
|
FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma
|
|
27 Jan 2011
|
Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
|
|
18 Jan 2011
|
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
|
|
13 Jan 2011
|
Genentech Informs Customers of Important Information About Triad Group's Alcohol Prep Pads
|
|
05 Jan 2011
|
FDA Grants Supplemental Approval for ACTEMRA® (tocilizumab)
|
|
16 Dec 2010
|
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
|
|
10 Dec 2010
|
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women with Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
|
|
05 Dec 2010
|
Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
|
|
05 Dec 2010
|
Phase II Study with First-in-Class Investigational Drug Demonstrates Improvement in Negative Symptoms in Patients with Schizophrenia
|
|
07 Nov 2010
|
ACTEMRA Data Presented at ACR Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthritis
|
|
04 Nov 2010
|
Genentech Reports Promising Phase II Results With New Targeted Approach in Advanced Melanoma
|
|
20 Oct 2010
|
FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
|
|
15 Oct 2010
|
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
|
|
17 Sep 2010
|
Genentech Provides Update on Avastin for Advanced Breast Cancer
|
|
26 Aug 2010
|
Genentech Provides Update on FDA Application for T-DM1
|
|
10 Aug 2010
|
FDA Approves Longer Use of Valcyte for Adult Kidney Transplant Patients at High Risk of Developing Cytomegalovirus (CMV) Disease
|
|
20 Jul 2010
|
Genentech Provides Update From Avastin FDA Advisory Committee Meeting
|
|
06 Jul 2010
|
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
|
|
01 Jul 2010
|
Second Phase III Study Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer Without their Disease Getting Worse
|
|
22 Jun 2010
|
FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
|
|
06 Jun 2010
|
Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease Worsening
|
|
03 Jun 2010
|
Genentech's Scheller Wins Kavli Prize in Neuroscience
|
|
20 May 2010
|
Roche and Genentech to Present New Data on Different Approaches to Treating Cancer at ASCO
|
|
20 May 2010
|
Phase III Study Showed First-Line Maintenance Use of Rituxan® Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening
|
|
22 Apr 2010
|
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
|
|
16 Apr 2010
|
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
|
|
16 Mar 2010
|
Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
|
|
11 Mar 2010
|
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
|
|
24 Feb 2010
|
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
|
|
22 Feb 2010
|
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
|
|
18 Feb 2010
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
|
|
15 Jan 2010
|
FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer
|
|
08 Jan 2010
|
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
|
|
16 Dec 2009
|
FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
|
|
12 Dec 2009
|
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
|
|
11 Dec 2009
|
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Women Previously Treated with Chemotherapy for Advanced Breast Cancer
|
|
10 Dec 2009
|
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
|
|
07 Dec 2009
|
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
|
|
18 Nov 2009
|
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
|
|
16 Nov 2009
|
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
|
|
17 Oct 2009
|
Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
|
|
17 Oct 2009
|
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
|
|
04 Oct 2009
|
Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
|
|
16 Sep 2009
|
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
|
|
17 Aug 2009
|
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
|
|
02 Aug 2009
|
FDA Approves Avastin for the Most Common Type of Kidney Cancer
|
|
30 Jul 2009
|
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
|
|
28 Jul 2009
|
Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
|
|
19 Jul 2009
|
Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
|
|
12 Jul 2009
|
New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
|
|
02 Jul 2009
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
|
|
30 May 2009
|
Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
|
|
30 May 2009
|
Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy
|
|
29 May 2009
|
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
|
|
19 May 2009
|
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
|
|
14 May 2009
|
Genentech to Present Advances With Targeted Cancer Medicines at ASCO
|
|
05 May 2009
|
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
|
|
21 Apr 2009
|
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
|
|
08 Apr 2009
|
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
|
|
31 Mar 2009
|
FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)
|
|
26 Mar 2009
|
Roche Completes Acquisition of Genentech
|
|
18 Mar 2009
|
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
|
|
12 Mar 2009
|
Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
|
|
11 Mar 2009
|
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
|
|
06 Mar 2009
|
Genentech Urges Stockholders to Take No Action With Respect to Revised Offer From Roche
|
|
24 Feb 2009
|
Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding
|
|
23 Feb 2009
|
Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate
|
|
23 Feb 2009
|
Genentech Announces March 2, 2009 Webcast of Investment Community Meeting
|
|
19 Feb 2009
|
National Coalition for Cancer Survivorship, UCLA, Wellpoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
|
|
09 Feb 2009
|
Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer from Roche
|
|
02 Feb 2009
|
Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
|
|
30 Jan 2009
|
Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer
|
|
21 Jan 2009
|
Genentech Announces Vice President Appointment in Research
|
|
15 Jan 2009
|
Genentech Announces Full Year And Fourth Quarter 2008 Results
|
|
22 Dec 2008
|
Genentech Announces January 15 Webcast of Financial and Other Business Results
|
|
18 Dec 2008
|
Phase III Study Showed Rituxan Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)
|
|
06 Dec 2008
|
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
|
|
23 Nov 2008
|
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
|
|
17 Nov 2008
|
Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient
|
|
06 Nov 2008
|
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
|
|
03 Nov 2008
|
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
|
|
27 Oct 2008
|
Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scientific Meeting
|
|
19 Oct 2008
|
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
|
|
14 Oct 2008
|
Genentech Announces Third Quarter 2008 Results
|
|
06 Oct 2008
|
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
|
|
05 Oct 2008
|
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
|
|
02 Oct 2008
|
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
|
|
02 Oct 2008
|
Genentech, Glycart and Roche Enter Into Collaboration Agreement for Potential Cancer Therapy
|
|
23 Sep 2008
|
Genentech Announces October 14 Webcast of Financial and Other Business Results
|
|
10 Sep 2008
|
Genentech Announces Vice President Appointment In Research
|
|
13 Aug 2008
|
Genentech Special Committee of Independent Directors Responds to Roche Proposal
|
|
24 Jul 2008
|
Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
|
|
21 Jul 2008
|
Genentech Announces Receipt of Proposal From Roche
|
|
14 Jul 2008
|
Genentech Announces Second Quarter 2008 Results
|
|
23 Jun 2008
|
Genentech Announces July 14 Webcast of Financial and Other Business Results
|
|
11 Jun 2008
|
Genentech Settles Dispute Related To Cabilly Patent
|
|
31 May 2008
|
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2-Negative Breast Cancer
|
|
19 May 2008
|
Genentech Announces June 2 Webcast Discussion of Data Presented at ASCO
|
|
15 May 2008
|
Genentech Provides Update on Avastin Program
|
|
15 May 2008
|
Genentech Provides Update On Studies Of Investigational Biooncology Agents To Be Presented At The American Society Of Clinical Oncology Meeting
|
|
29 Apr 2008
|
Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
|
|
24 Apr 2008
|
Genentech Announces Decision In Contract Dispute
|
|
20 Apr 2008
|
Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
|
|
15 Apr 2008
|
Genentech Extends Stock Repurchase Program
|
|
14 Apr 2008
|
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
|
|
10 Apr 2008
|
Genentech Announces First Quarter 2008 Results
|
|
21 Mar 2008
|
Genentech Announces April 10 Webcast of Financial and Other Business Results
|
|
14 Mar 2008
|
Genentech Provides Business Update At Annual Investment Community Meeting
|
|
03 Mar 2008
|
Genentech Announces March 14 Webcast of Investment Community Meeting
|
|
25 Feb 2008
|
Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
|
|
22 Feb 2008
|
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
|
|
12 Feb 2008
|
Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer
|
|
24 Jan 2008
|
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
|
|
14 Jan 2008
|
Genentech Announces Full Year and Fourth Quarter 2007 Results
|
|
20 Dec 2007
|
Genentech Announces January 14 Webcast Discussion of Financial and Other Business Results
|
|
05 Dec 2007
|
Genentech Provides Update From Avastin FDA Advisory Meeting
|
|
20 Nov 2007
|
Genentech Foundation for Biomedical Sciences Awards Nearly $1.2 Million to Health Science Education Programs in the Bay Area
|
|
18 Nov 2007
|
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
|
|
15 Oct 2007
|
Genentech Announces Third Quarter 2007 Results
|
|
24 Sep 2007
|
Genentech Announces October 15 Webcast Discussion of Earnings and Other Business Results
|
|
24 Aug 2007
|
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
|
|
02 Aug 2007
|
Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox
|
|
11 Jul 2007
|
Genentech Announces Second Quarter 2007 Results
|
|
26 Jun 2007
|
Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
|
|
20 Jun 2007
|
Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
|
|
04 Jun 2007
|
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
|
|
03 Jun 2007
|
Genentech Provides Update on Pipeline Agents at The American Society of Clinical Oncology Meeting
|
|
02 Jun 2007
|
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
|
|
02 Jun 2007
|
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer
|
|
11 May 2007
|
Genentech Announces June 4 Webcast Discussion of Data Presented at ASCO
|
|
01 May 2007
|
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
|
|
20 Apr 2007
|
Genentech Extends Stock Repurchase Program
|
|
11 Apr 2007
|
Genentech Announces First Quarter 2007 Results
|
|
23 Mar 2007
|
Genentech to Provide Business Update at Annual Investment Community Meeting
|
|
21 Mar 2007
|
Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
|
|
09 Mar 2007
|
Genentech Announces March 23 Webcast of Investment Community Meeting
|
|
21 Feb 2007
|
Analysis of International Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
|
|
21 Feb 2007
|
Genentech Provides Update on Cabilly Patent Reexamination
|
|
14 Feb 2007
|
Genentech Announces Additional Effort to Support Patient Access
|
|
02 Feb 2007
|
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
|
|
29 Jan 2007
|
Genentech and Tanox Receive "Second Request" from the Federal Trade Commission
|
|
17 Jan 2007
|
Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
|
|
10 Jan 2007
|
Genentech Announces Full Year and Fourth Quarter 2006 Results
|
|
08 Jan 2007
|
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
|
|
08 Jan 2007
|
Genentech Again Named One of FORTUNE's "100 Best Companies to Work For"
|
|
04 Jan 2007
|
Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab in Combination with Gemcitabine for Advanced Ovarian Cancer
|
|
20 Dec 2006
|
Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
|
|
14 Dec 2006
|
Key Herceptin Data Presented at San Antonio Breast Cancer Symposium
|
|
13 Dec 2006
|
New England Journal of Medicine Publishes Data From Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
|
|
11 Dec 2006
|
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
|
|
16 Nov 2006
|
FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
|
|
11 Nov 2006
|
Subsequent Course of Rituxan Improved Outcomes in Rheumatoid Arthritis Patients Who Inadequately Responded to TNF Antagonist Therapy
|
|
09 Nov 2006
|
Genentech Announces Agreement to Acquire Tanox for $20 Per Share
|
|
07 Nov 2006
|
Genentech Announces Manufacturing Agreements With Lonza
|
|
11 Oct 2006
|
FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
|
|
10 Oct 2006
|
Genentech Announces Third Quarter 2006 Results
|
|
04 Oct 2006
|
Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
|
|
04 Oct 2006
|
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
|
|
03 Oct 2006
|
Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications
|
|
29 Sep 2006
|
FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma
|
|
19 Sep 2006
|
Genentech Announces October 10 Webcast Discussion of Third Quarter Earnings and Other Business Results
|
|
11 Sep 2006
|
Genentech Receives Complete Response Letter From FDA for Avastin in Metastatic Breast Cancer
|
|
28 Aug 2006
|
Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
|
|
17 Aug 2006
|
Genentech Foundation for Biomedical Sciences Awards $1.2 Million to Health Science Education Programs in the Bay Area
|
|
11 Aug 2006
|
Genentech Provides Update On Supplemental Biologics License Application For Adjuvant Herceptin In Early-Stage Her2-Positive Breast Cancer
|
|
26 Jul 2006
|
Genentech Announces Vice President and Officer Appointments in Product Development and Finance
|
|
25 Jul 2006
|
Genentech & Inotek Enter into Exclusive Global Strategic Alliance for the Discovery, Development and Commercialization of PARP Inhibitors for Cancer
|
|
11 Jul 2006
|
Genentech Announces Second Quarter 2006 Results
|
|
30 Jun 2006
|
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
|
|
26 Jun 2006
|
Phase III Study of Avastin in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
|
|
22 Jun 2006
|
Analysis of Phase III Study Showed Rituxan Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
|
|
20 Jun 2006
|
Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
|
|
20 Jun 2006
|
FDA Approves Avastin in Combination with Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
|
|
05 Jun 2006
|
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin Plus Tarceva and Avastin Plus Chemotherapy Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer
|
|
02 Jun 2006
|
Preliminary Results from a Phase IIIb Study Showed Patients with Wet AMD Treated with Lucentis Quarterly Experienced a 16-Letter Benefit over the Control Group at One Year
|
|
25 May 2006
|
Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line Metastatic Breast Cancer
|
|
22 May 2006
|
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
|
|
22 May 2006
|
Genentech Announces June 5 Webcast Discussion of Data Presented at ASCO
|
|
19 May 2006
|
Genentech Announces June 2 Webcast Discussion Of Lucentis Data Presented At The 2006 Retinal Physician Symposium
|
|
11 May 2006
|
Genentech Announces Vice President Appointments In Commercial Operations And Product Development
|
|
21 Apr 2006
|
Genentech Extends Stock Repurchase Program
|
|
11 Apr 2006
|
Genentech Announces First Quarter 2006 Results
|
|
11 Apr 2006
|
Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
|
|
10 Apr 2006
|
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
|
|
30 Mar 2006
|
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
|
|
23 Mar 2006
|
Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
|
|
17 Mar 2006
|
Genentech Provides Updates at Annual Investment Meeting
|
|
03 Mar 2006
|
Genentech Announces March 17 Webcast of Investment Community Meeting
|
|
28 Feb 2006
|
FDA Approves Rituxan - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
|
|
28 Feb 2006
|
Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
|
|
15 Feb 2006
|
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin in Early-Stage HER2-Positive Breast Cancer
|
|
12 Feb 2006
|
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
|
|
10 Feb 2006
|
FDA Approves Rituxan Plus CHOP or other Anthracycline-Based Chemotherapy Regimens for First-Line Treatment of Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
|
26 Jan 2006
|
Amgen and Genentech Sign License Agreements for Antibody Patents
|
|
14 Jan 2006
|
Preliminary Phase III Data from Head-to-Head Study of Lucentis Shows Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration
|
|
10 Jan 2006
|
Genentech Announces Full Year and Fourth Quarter 2005 Results
|
|
09 Jan 2006
|
Genentech Announces Vice President Appointments in Commercial Operations, Corporate Information Technology, Product Development and Product Operations
|
|
09 Jan 2006
|
Genentech Named Number 1 on FORTUNE's 100 Best Companies to Work For
|
|
06 Jan 2006
|
Genentech Announces January 14th Webcast Discussion Of Data Presented At Macula 2006 Meeting
|
|
05 Jan 2006
|
Genentech Announces Executive Promotions
|
|
30 Dec 2005
|
Genentech Submits Biologics License Application for FDA Review of Lucentis in Wet Age-Related Macular Degeneration
|
|
21 Dec 2005
|
Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
|
|
19 Dec 2005
|
Genentech Submits Supplemental Biologics License Application for Avastin in Relapsed Metastatic Colorectal Cancer
|
|
10 Nov 2005
|
Biogen Idec and Genentech Announce November 16th Webcast Discussion of Rituxan Data Presented at ACR
|
|
07 Nov 2005
|
Preliminary Data from Phase III Trial Show Lucentis is the First Investigational Therapy to Demonstrate Clinical Benefit over Visudyne in a Head-to-Head Study of Patients with Wet AMD
|
|
02 Nov 2005
|
FDA Approves Tarceva in Combination with Gemcitabine Chemotherapy for Treatment of Locally Advanced, Inoperable or Metastatic Pancreatic Cancer
|
|
31 Oct 2005
|
Biogen Idec and Genentech Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for Rituxan in Rheumatoid Arthritis
|
|
25 Oct 2005
|
FDA Grants Priorty Review for Rituxan Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
|
|
19 Oct 2005
|
Pivotal Herceptin Data in the New England Journal of Medicine Showed Significant Improvement in Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
|
|
19 Oct 2005
|
Genentech and ABC2 Announce Second Brain Cancer Collaboration
|
|
18 Oct 2005
|
Genentech Announces Preliminary Results from Randomized Phase II Trial of Avastin and Tarceva in Kidney Cancer
|
|
10 Oct 2005
|
Genentech Announces Third Quarter 2005 Results
|
|
27 Sep 2005
|
Genentech Provides Information on Patent Reexamination
|
|
23 Sep 2005
|
Genentech Provides Update on Phase II Study with Avastin in Platinum-Refractory Ovarian Cancer
|
|
19 Sep 2005
|
Genentech Announces October 10 Webcast Discussion of Earnings and Other Business Results
|
|
13 Sep 2005
|
Fourth Phase III Study Shows Herceptin Plus Chemotherapy Improved Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
|
|
13 Sep 2005
|
FDA Advisory Panel Recommends Tarceva Approval for Pancreatic Cancer
|
|
07 Sep 2005
|
Genentech Announces Plans to File for FDA Approval of Lucentis for the Treatment of Wet Age-Related Macular Degeneration in December
|
|
31 Aug 2005
|
Biogen Idec and Genentech Submit a Supplemental Biologics License Application for FDA Review of Rituxan for the Treatment of Rheumatoid Arthritis
|
|
17 Aug 2005
|
Genentech and Biogen Idec File Supplemental Biologics License Application for FDA Review of Rituxan for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-Positive, B-Cell, Non-Hodgkin's Lymphoma
|
|
16 Aug 2005
|
Genentech Announces Organizational Changes
|
|
29 Jul 2005
|
Genentech Foundation for Biomedical Sciences Bolsters Innovation in Health Science Education with $1.2 Million for Bay Area Programs
|
|
18 Jul 2005
|
Phase III Study Shows Lucentis Improved Vision in Patients With Wet Age-Related Macular Degeneration
|
|
18 Jul 2005
|
Preliminary Phase I/II Study Showed Lucentis Improved Vision in Patients with Wet Age-Related Macular Degeneration When Used in Combination with Visudyne
|
|
13 Jul 2005
|
Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
|
|
13 Jul 2005
|
Genentech Announces Intention to Offer up to $2 Billion in Senior Notes
|
|
13 Jul 2005
|
Genentech Announces Pricing of $2 Billion in Senior Notes
|
|
11 Jul 2005
|
Genentech Announces Second Quarter 2005 Results
|
|
05 Jul 2005
|
Genentech Announces July 18 Webcast Discussion of Data Presented at ASRS
|
|
28 Jun 2005
|
Genentech Announces Vice President Appointments in Product Operations, Regulatory, and Research
|
|
24 Jun 2005
|
Genentech Provides Manufacturing Update
|
|
23 Jun 2005
|
Genentech Announces June 24 Webcast Discussion of Recent Manufacturing Activities
|
|
20 Jun 2005
|
Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
|
|
16 Jun 2005
|
Biologics Manufacturing Facility to be Purchased by Genentech from Biogen Idec
|
|
15 Jun 2005
|
Genentech Extends Share Repurchase Program
|
|
09 Jun 2005
|
Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumatic Drugs
|
|
31 May 2005
|
Preliminary Phase I/II Data Show Lucentis in Combination With Visudyne Maintained or Improved Vision in Approximately 90 Percent of Patients With Wet Age-Related Macular Degeneration
|
|
23 May 2005
|
Preliminary Phase III Data Show Lucentis Maintained or Improved Vision in Nearly 95 Percent of Patients with Wet Age-Related Macular Degeneration
|
|
15 May 2005
|
Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting
|
|
14 May 2005
|
Phase III Study of Tarceva in Combination with Chemotherapy Improves Survival in Pancreatic Cancer Patients
|
|
13 May 2005
|
Phase III Trial of Avastin Plus Chemotherapy Showed 30 Percent Improvement in Overall Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
|
|
13 May 2005
|
Avastin Plus Chemotherapy Showed Doubling of Time Without Cancer Progression in Phase III Trial of
First-Line Metastatic Breast Cancer Patients
|
|
13 May 2005
|
Herceptin Plus Chemotherapy Improved Disease-Free Survival and Overall Survival in Adjuvant Setting for Early-Stage Her2-Positive Breast Cancer Patients
|
|
04 May 2005
|
Genentech Announces Vice President Appointments in Product Operations and Product Development
|
|
04 May 2005
|
Genentech Announces Webcast Discussions of Data Presented at ASCO; Phase III Breast Cancer Studies to be Presented at Educational Session
|
|
02 May 2005
|
OSI Pharmaceuticals and Genentech Announce Filing of a Supplemental New Drug Application to the FDA for Tarceva in Pancreatic Cancer
|
|
25 Apr 2005
|
Interim Analysis of Phase III Studies Shows Herceptin Plus Chemotherapy Improves Disease-Free Survival in the Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
|
|
14 Apr 2005
|
Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Improved Progression-Free Survival in Patients with First-Line Metastatic Breast Cancer
|
|
11 Apr 2005
|
Genentech Announces First Quarter 2005 Results
|
|
05 Apr 2005
|
Phase III Study Shows Rituxan Significantly Improves Symptoms in Patients with Rheumatoid Arthritis Who Inadequately Responded to Anti-TNF Therapies
|
|
21 Mar 2005
|
Genentech and Ipsen Agree to Develop Sustained-Release Formulations of Recombinant Human Growth Hormone
|
|
21 Mar 2005
|
Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
|
|
14 Mar 2005
|
Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Extends Survival of Patients with First-Line Non-Squamous, Non-Small Cell Lung Cancer
|
|
04 Mar 2005
|
Genentech Announces Strategic Updates at Investment Meeting
|
|
25 Feb 2005
|
Genentech Announces March 4 Webcast of Investment Community Meeting
|
|
18 Feb 2005
|
Three-Year Study with Raptiva Showed Long-Term and Sustained Clearing in Moderate-to-Severe Plaque Psoriasis Patients
|
|
27 Jan 2005
|
Preliminary Positive Results from Phase III Trial of Avastin Plus FOLFOX4 Chemotherapy Presented at ASCO GI Meeting
|
|
27 Jan 2005
|
Data From Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients
|
|
10 Jan 2005
|
Genentech Again Named One of FORTUNE's "100 Best Companies To Work For"
|
|
10 Jan 2005
|
Genentech Announces Fourth Quarter and Full Year 2004 Results
|
|
06 Jan 2005
|
Genentech Finalizes Avastin Label with Previously Announced Safety Information
|
|
22 Dec 2004
|
Genentech Board Announces Executive Promotions and Senior Appointments in Commercial Operations, Finance and Manufacturing
|
|
21 Dec 2004
|
Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
|
|
29 Nov 2004
|
Phase III Results Show Avastin Plus Folfox4 Chemotherapy Significantly Extend Survival in Second-Line Metastatic Colorectal Cancer
|
|
25 Nov 2004
|
Genentech Again Named the No. 1 Employer in Science Magazine Survey
|
|
18 Nov 2004
|
FDA Approves Tarceva for Patients with Advanced Non-Small Cell Lung Cancer
|
|
18 Nov 2004
|
Genentech Announces November 18 Webcast Discussion of Tarceva FDA Approval
|
|
10 Nov 2004
|
Genentech Announces Organizational Changes
|
|
09 Nov 2004
|
Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain
|
|
04 Nov 2004
|
Genentech Announces Senior Appointments in Manufacturing and Engineering
|
|
01 Nov 2004
|
Preliminary Phase IIb Data Show Rituxan Improved Symptoms in Patients with Moderate-to-Severe Rheumatoid Arthritis
|
|
21 Oct 2004
|
Genentech to Seek Review of Court Decision in Contract Dispute
|
|
06 Oct 2004
|
Genentech Announces Third Quarter 2004 Results
|
|
04 Oct 2004
|
Genentech Receives Subpoena on Rituxan
|
|
28 Sep 2004
|
Genentech Extends Share Repurchase Program
|
|
23 Sep 2004
|
Genentech and Wyeth Announce Manufacturing Agreement
|
|
20 Sep 2004
|
Tarceva Plus Gemcitabine Improves Survival Compared to Gemcitabine Alone in First-Line Pancreatic Cancer Patients
|
|
15 Sep 2004
|
Genentech Announces October 6 Webcast Discussion of Earnings and Other Business Results
|
|
10 Sep 2004
|
Genentech and OSI Pharmaceuticals Initiate Phase IIIB Clinical Trial of Tarceva in Advanced Non-Small Cell Lung Cancer
|
|
02 Sep 2004
|
Giants and Genentech Devote Sunday, September 5 to Striking Out Cancer
|
|
10 Aug 2004
|
Genentech Announces FDA Approval of Avastin Manufacturing at Vacaville Facility
|
|
02 Aug 2004
|
OSI Pharmaceuticals and Genentech Announce Completion of New Drug Application for FDA Approval of Tarceva
|
|
29 Jul 2004
|
Preliminary Data Showed Sustained Clinical Benefit for Moderate-to-Severe Plaque Psoriasis Patients Treated with Raptiva for 30 Months
|
|
07 Jul 2004
|
Genentech Announces Second Quarter 2004 Results
|
|
30 Jun 2004
|
Genentech Announces Senior Appointments in Commercial Operations and Development
|
|
17 Jun 2004
|
Genentech Announces July 7 Webcast Discussion of Earnings and Other Business Results
|
|
16 Jun 2004
|
OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing Agreements for Tarceva
|
|
16 Jun 2004
|
Positive Data from Preliminary Phase II Study of Rituxan in Rheumatoid Arthritis Published in the New England Journal Of Medicine
|
|
08 Jun 2004
|
Genentech Presents Data from Broad Avastin Clinical Trial Program at the American Society of Clinical Oncology Meeting
|
|
07 Jun 2004
|
Key Herceptin Data Presented at American Society of Clinical Oncology Meeting
|
|
05 Jun 2004
|
Preliminary Phase III Data Showed Front-Line Use of Rituxan Plus Chemotherapy Improved Survival in Patients Under 60 with Aggressive Non-Hodgkin's Lymphoma
|
|
05 Jun 2004
|
Preliminary Results of a Phase III Study Showed Rituxan Maintenance Therapy Improved Progression-Free Survival in Newly Diagnosed Patients with Indolent Non-Hodgkin's Lymphoma
|
|
05 Jun 2004
|
Early Clinical Data Evaluating the Combination of Avastin and Tarceva Yield Initial Promising Results in Several Cancers
|
|
05 Jun 2004
|
Phase III Study of Tarceva in Relapsed Non-Small Cell Lung Cancer Shows Significant Improvement in Survival
|
|
02 Jun 2004
|
Pivotal Avastin Study in New England Journal of Medicine Showed Significant Improvement in Patients with Metastatic Colorectal Cancer
|
|
01 Jun 2004
|
Genentech and Alkermes Announce Decision to Discontinue Commercialization of Nutropin Depot
|
|
21 May 2004
|
Genentech Announces Webcast Discussions of Data Presented at ASCO
|
|
18 May 2004
|
Genentech Foundation for Biomedical Sciences Awards More Than $1 Million to Science Education Programs in the Bay Area
|
|
25 Apr 2004
|
Tarceva Extends Survival of Patients with Relapsed Non-Small Cell Lung Cancer
|
|
16 Apr 2004
|
Genentech Announces Approval of Two-for-One Stock Split
|
|
07 Apr 2004
|
Genentech Announces First Quarter 2004 Results - Increase of 28 Percent in Product Sales
|
|
06 Apr 2004
|
Genentech Win in Chiron Patent Litigation Unanimously Affirmed by U.S. Court of Appeals
|
|
24 Mar 2004
|
Genentech Announces Senior Appointment in Corporate Information Technology
|
|
21 Mar 2004
|
Genentech and XOMA Announce Results of Phase II Study of Raptiva in Psoriatic Arthritis Patients
|
|
12 Mar 2004
|
Genentech Announces Long-Term Strategy and Financial Goals
|
|
10 Mar 2004
|
Genentech Announces April 7 Webcast Discussion of Earnings and Other Business Results
|
|
09 Mar 2004
|
Genentech Announces Organizational Changes
|
|
03 Mar 2004
|
Genentech's Board of Directors Approves a Conditional Stock Split
|
|
02 Mar 2004
|
Genentech Announces March 12 Webcast of Investment Community Meeting
|
|
26 Feb 2004
|
Genentech, Novartis and Tanox Settle Disputes Surrounding Xolair and TNX-901
|
|
26 Feb 2004
|
FDA Approves Avastin, a Targeted Therapy for First-Line Metastatic Colorectal Cancer Patients
|
|
16 Jan 2004
|
Genentech Announces Senior Appointments in Development, Commercial and Manufacturing
|
|
14 Jan 2004
|
Genentech Reports $3.3 Billion in Revenues with $1.9 Billion in Oncology Sales
|
|
07 Jan 2004
|
Genentech Announces Webcast of Presentation at JP Morgan 22nd Annual Healthcare Conference
|
|
29 Dec 2003
|
Genentech Named Number 15 on Fortune's "Best Companies To Work For" List
|
|
15 Dec 2003
|
Genentech Announces January 14 Webcast Discussion of Earnings and Other Business Results
|
|
15 Dec 2003
|
Genentech and Lonza Announce Manufacturing Agreement
|
|
08 Dec 2003
|
Initial Results of a Randomized Phase II Study Suggest that Rituxan Maintenance Therapy Prolongs Remission in Indolent NHL
|
|
07 Dec 2003
|
Initial Data from Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma (NHL) Presented at ASH
|
|
07 Dec 2003
|
Initial Results of a New Study of Rituxan Plus CVP Chemotherapy Demonstrate Prolonged Time to Treatment Failure as Front-Line Therapy for Patients with Indolent Non-Hodgkin's Lymphoma
|
|
07 Dec 2003
|
Phase III Trial of Rituxan Plus Chemotherapy as a Front-Line Therapy in Aggressive Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Two Years Early
|
|
05 Dec 2003
|
Genentech Announces Share Repurchase Program
|
|
04 Dec 2003
|
Preliminary Results of a Phase II Study of Herceptin and Taxotere (docetaxel) Combination Suggests Improved Survival in HER2-Positive Metastatic Breast Cancer Patients
|
|
01 Dec 2003
|
Genentech Announces FDA Acceptance of Biologics License Application with Priority Review of Avastin In First-Line Metastatic Colorectal Cancer
|
|
25 Nov 2003
|
Genentech Reports Results from Phase II Trial of Avastin in Metastatic Colorectal Cancer
|
|
24 Nov 2003
|
Genentech Announces December 7th Webcast Discussion of Data Presented at ASH
|
|
19 Nov 2003
|
Study in New England Journal of Medicine Shows Extending Raptiva (efalizumab) Treatment Provides Rapid and Continuous Benefit
|
|
13 Nov 2003
|
Eastern Cooperative Oncology Group (ECOG) Phase III Trial of Rituxan Maintenance Therapy in Indolent Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Early
|
|
11 Nov 2003
|
Boehringer Ingelheim and Genentech Announce Initiation of a Clinical Trial Evaluating TNKase/Metalyse Use Prior to Angioplasty for Treatment of Heart Attack
|
|
10 Nov 2003
|
Genentech Named to "Scientific American 50" List
|
|
04 Nov 2003
|
Initial Data Released From Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma
|
|
27 Oct 2003
|
FDA Approves Raptiva (efalizumab) for Chronic Moderate-to-Severe Plaque Psoriasis
|
|
26 Oct 2003
|
Follow-Up Data from Phase II Study of Rituxan as a Potential Treatment for Rheumatoid Arthritis Show Durability of Response at 48 Weeks
|
|
23 Oct 2003
|
Genentech Named the No. 1 Rated Employer in Science Magazine Survey
|
|
08 Oct 2003
|
Genentech Reports 17 Percent Increase in Non-GAAP Earnings Per Share for Third Quarter 2003
|
|
07 Oct 2003
|
Genentech Announces Senior Appointments in Commercial Operations and Research
|
|
01 Oct 2003
|
Phase III Trials of Tarceva(TM) Plus Chemotherapy in First-Line Non-Small Cell Lung Cancer Do Not Meet Primary Efficacy Endpoint
|
|
29 Sep 2003
|
Genentech Files Biologics License Application for FDA Approval of Avastin in First-Line Metastatic Colorectal Cancer
|
|
24 Sep 2003
|
Genentech Announces October 8 Webcast Discussion of Earnings and Other Business Results
|
|
09 Sep 2003
|
FDA Advisory Committee Unanimously Recommends Approval for Raptiva as a Potential Treatment for Moderate-to-Severe Plaque Psoriasis
|
|
03 Sep 2003
|
Genentech Appoints Marc Tessier-Lavigne to Senior Vice President, Research Drug Discovery
|
|
03 Sep 2003
|
Genentech Promotes Richard Scheller to Executive Vice President, Research
|
|
02 Sep 2003
|
Genentech Announces September 9th Webcast Discussion of DODAC Review of Raptiva BLA
|
|
27 Aug 2003
|
Genentech and Amgen Settle Patent Dispute
|
|
18 Aug 2003
|
Genentech Presents Positive Preliminary Six-Month Data from Phase Ib/II Study for Lucentis in Age-Related Macular Degeneration (AMD)
|
|
08 Aug 2003
|
Tarceva (erlotinib HCl) Phase II Clinical Trial Initiated in Patients with Malignant Glioma
|
|
31 Jul 2003
|
Genentech and XOMA Announce FDA Advisory Committee Review of Raptiva
|
|
26 Jul 2003
|
New Data Support Raptiva as a Potential Long-Term Treatment for Moderate-to-Severe Plaque Psoriasis
|
|
17 Jul 2003
|
Genentech Announces Senior Appointments in Research and Commercial Operations
|
|
09 Jul 2003
|
Genentech Reports 35 Percent Increase in Non-GAAP Earnings Per Share for Second Quarter
|
|
26 Jun 2003
|
Genentech Receives FDA Fast-Track Designation for Avastin
|
|
25 Jun 2003
|
Genentech Announces July 9 Webcast Discussion of Earnings and Other Business Results
|
|
24 Jun 2003
|
Genentech and Novartis Ophthalmics Announce Development and Commercialization Agreement for Age-Related Macular Degeneration Treatment, Lucentis
|
|
20 Jun 2003
|
FDA Approves Xolair, Biotechnology Breakthrough for Asthma
|
|
20 Jun 2003
|
Genentech and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration
|
|
17 Jun 2003
|
Genentech and Biogen Announce Autoimmune Collaboration
|
|
02 Jun 2003
|
Clinical Data from Phase II Study in Early Breast Cancer Suggest Potential Use of Herceptin with New Chemotherapy Combination
|
|
01 Jun 2003
|
Genentech Reports Additional Data from BioOncology Pipeline at ASCO
|
|
01 Jun 2003
|
Positive Results from Phase III Avastin Study in Metastatic Colorectal Cancer Presented at ASCO
|
|
31 May 2003
|
Preliminary Positive Data From Rituxan Multi-Center Trial in First-Line and Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia (CLL)
|
|
31 May 2003
|
Tarceva (erlotinib HCl) Shows Encouraging Safety Profile and Activity in Phase I Clinical Study in Patients with Malignant Glioma
|
|
29 May 2003
|
Genentech Names Corsee Sanders Vice President, Biometrics and Business Operations, Medical Affairs
|
|
23 May 2003
|
Genentech Announces June 1st Webcast Discussion of Data Presented at ASCO
|
|
19 May 2003
|
Phase III Trial of Avastin Plus Chemotherapy Markedly Extends Survival of Metastatic Colorectal Cancer Patients
|
|
15 May 2003
|
FDA Advisory Committee Unanimously Recommends Approval of Xolair
|
|
12 May 2003
|
Genentech and XOMA Discontinue Rheumatoid Arthritis Trial
|
|
08 May 2003
|
Genentech And ABC(2) Agree to Collaborate on Brain Cancer Clinical Trial
|
|
08 May 2003
|
Genentech Announces May 15th Webcast Discussion of PADAC Review of Xolair BLA
|
|
16 Apr 2003
|
Genentech Announces April 23 Webcast of Annual Meeting of Stockholders
|
|
10 Apr 2003
|
Genentech Foundation for Biomedical Sciences Awards $1 Million to Science Education Programs in the Bay Area
|
|
09 Apr 2003
|
Genentech Reports 59 Percent Increase in Non-GAAP Earnings Per Share for First Quarter
|
|
27 Mar 2003
|
Genentech, Novartis and Tanox Announce FDA Advisory Committee Review of Xolair (Omalizumab)
|
|
26 Mar 2003
|
Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
|
|
22 Mar 2003
|
Preliminary Results from Open-Label Raptiva Study Suggest Continued Benefit with Long-Term Treatment
|
|
21 Mar 2003
|
Phase III Study Results with Raptiva in the Treatment of Psoriasis Presented at Annual AAD Meeting
|
|
14 Mar 2003
|
Genentech Projects Double-Digit Growth for 2005-2010
|
|
12 Mar 2003
|
Genentech Appoints Philippa Norman Vice President, Global Supply Chain
|
|
07 Mar 2003
|
Genentech Announces March 21 Webcast Discussion of Data Presented at the American Academy of Dermatology
|
|
03 Mar 2003
|
Genentech Announces March 14 Webcast of Investment Community Meeting
|
|
27 Jan 2003
|
Genentech Appoints Ian Clark Senior Vice President and General Manager, BioOncology
|
|
15 Jan 2003
|
Genentech Exceeds $2.7 Billion in Revenues with $1.5 Billion in Oncology Sales
|
|
06 Jan 2003
|
Genentech Named One of Fortune's "100 Best Companies To Work For"
|
|
06 Jan 2003
|
Genentech Announces Webcast of Presentation at JP Morgan 21st Annual Healthcare Conference
|
|
02 Jan 2003
|
Genentech Announces January 15 Webcast Discussion of Earnings and Other Business Results
|
|
23 Dec 2002
|
Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva(TM) (Efalizumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis
|
|
18 Dec 2002
|
Genentech and Novartis Submit Amendment to the Biologics License Application for Xolair (TM) (Omalizumab) to FDA
|
|
11 Dec 2002
|
Preliminary Results from Phase III Study Demonstrate Herceptin/Chemotherapy Combination Delays Time to Disease Progression in HER2-Positive Breast Cancer
|
|
09 Dec 2002
|
Investigational Data Demonstrate Potential of Extended Rituxan(R) Use to Increase Event-Free Survival in Patients with Indolent NHL
|
|
20 Nov 2002
|
Pre-Hospital Thrombolytic Treatment of Heart Attack Found Feasible and Faster Than In-Hospital Therapy
|
|
28 Oct 2002
|
Preliminary Positive Data from Investigational Randomized Phase II Trial Demonstrates Rituxan as a Potential Treatment for Rheumatoid Arthritis
|
|
09 Oct 2002
|
Genentech Reports 23 Percent Increase in Product Sales for Third Quarter
|
|
07 Oct 2002
|
Genentech Announces Senior Appointments in Medical Affairs and Research
|
|
01 Oct 2002
|
Genentech Announces Preliminary Positive Phase Ib/II Data for rhuFab V2 in Age-Related Macular Degeneration (AMD)
|
|
26 Sep 2002
|
Genentech Announces October 9 Webcast Discussion of Earnings and Other Business Results
|
|
24 Sep 2002
|
Genentech Recognized as One of The 100 Best Companies for Working Mothers
|
|
19 Sep 2002
|
Genentech Listed as Top Employer in Science Survey
|
|
17 Sep 2002
|
Genentech and XOMA Announce Phase III Study with Raptiva(TM) Achieves Primary Efficacy Endpoint
|
|
09 Sep 2002
|
Phase III Trial With Avastin(TM) in Relapsed Metastatic Breast Cancer Does Not Meet Primary Endpoint
|
|
06 Sep 2002
|
Genentech Wins Patent Dispute With Chiron
|
|
04 Sep 2002
|
Genentech Names Stephen G. Juelsgaard Executive Vice President
|
|
29 Aug 2002
|
Genentech Receives FDA Approval to Include HER2 Gene Detection Test in Herceptin(R) Product Labeling
|
|
19 Aug 2002
|
Genentech Extends Stock Repurchase Program
|
|
19 Aug 2002
|
OSI Pharmaceuticals and Genentech Provide Update on Status of Tarceva Program
|
|
15 Aug 2002
|
U.S. PTO Interference Declared in Genentech/Chiron Patent Dispute
|
|
07 Aug 2002
|
Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva
|
|
02 Aug 2002
|
Genentech and XOMA Announce Preliminary Data from Long-Term Study with Investigational Psoriasis Therapy
|
|
01 Aug 2002
|
Tarceva U.S. Phase III Non-Small Cell Lung Cancer Clinical Trial Completes Patient Enrollment
|
|
10 Jul 2002
|
Genentech Reports 28 Percent Increase in Product Sales for Second Quarter
|
|
24 Jun 2002
|
Genentech to Appeal Judgment in Contract Dispute
|
|
20 Jun 2002
|
Genentech Announces July 10 Webcast Discussion of Earnings and Other Business Results
|
|
18 Jun 2002
|
Preliminary Data from Phase II Study of Rituxan for Rheumatoid Arthritis are Positive
|
|
17 Jun 2002
|
Investigational Data from Randomized Study of Extended Therapy with Rituxan(R) Demonstrates Potential to Delay Disease Progression in Patients with Indolent NHL
|
|
10 Jun 2002
|
Genentech Announces Verdict in Contract Dispute
|
|
21 May 2002
|
Investigational Data Demonstrates Potential Use of Rituxan in Various CD20-Positive Cancers
|
|
20 May 2002
|
National Cancer Institute (NCI) Study Demonstrates Genentech's Investigational Anti-Angiogenesis Treatment Avastin(TM) Delays Time to Disease Progression in Metastatic Kidney Cancer
|
|
14 May 2002
|
Genentech and OSI Pharmaceuticals Announce FDA Fast-Track Designation for Tarceva(tm)
|
|
14 May 2002
|
Genentech Appoints Hal Barron Vice President, Medical Affairs
|
|
09 May 2002
|
Genentech Invites Investors to Listen to Webcast of May 21 Discussion of ASCO Presentations
|
|
23 Apr 2002
|
FDA Approves Nutropin AQ PEN (TM) For Delivery Of Nutropin AQ (R) Recombinant Growth Hormone
|
|
22 Apr 2002
|
Genentech Foundation for Biomedical Sciences Awards $869,411 to Support Quality Science Education in the Bay Area
|
|
09 Apr 2002
|
Genentech Reports 22 Percent Increase in Product Sales For First Quarter
|
|
05 Apr 2002
|
Genentech and Xoma Obtain Results from Xanelim(TM) (Efalizumab) Pharmacokinetic Study
|
|
25 Mar 2002
|
Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
|
|
05 Mar 2002
|
Genentech Names Gene Murano Vice President, Regulatory Affairs
|
|
25 Feb 2002
|
Genentech to Collaborate with ABC2 for Brain Cancer Research
|
|
25 Feb 2002
|
Xanelim (Efalizumab) Study Results Presented at 60th Annual American Academy of Dermatology Meeting
|
|
06 Feb 2002
|
Phase III Tracleer (bosentan) Study in Chronic Heart Failure Does Not Meet Primary Efficacy Objective
|
|
28 Jan 2002
|
Genentech Names Mark Ahn Vice President, Hematology Sales and Marketing
|
|
23 Jan 2002
|
New England Journal of Medicine Study Shows 53 Percent Increase in Event-Free Survival in Patients Treated with Rituxan and CHOP Chemotherapy
|
|
21 Jan 2002
|
Genentech Named One of Fortune's "100 Best Companies To Work For"
|
|
16 Jan 2002
|
Genentech Exceeds $2 Billion in Revenues with $1 Billion in Oncology Sales
|
|
20 Dec 2001
|
Genentech Announces January 16 Webcast Discussion of Earnings and Other Business Results
|
|
18 Dec 2001
|
Genentech Granted Fundamental U.S. Patent for Antibody Technology
|
|
12 Dec 2001
|
Genentech Receives FDA Approval to Add Survival Data to Herceptin Product Labeling
|
|
10 Dec 2001
|
Investigational Data Presented on Use of Rituxan in the Treatment of Immune Thrombocytopenic Purpura (ITP)
|
|
10 Dec 2001
|
Potential Extended Survival Benefit Shown with Rituxan and Chop Chemotherapy Study as Front-Line Therapy in Common Forms of Non-Hodgkin's Lymphoma (NHL)
|
|
10 Dec 2001
|
Clinical Trial Data Presented on Rituxan with Chemotherapy as Front-Line Treatment in Chronic Lymphocytic Leukemia (CLL)
|
|
07 Dec 2001
|
Key Milestones Achieved in Genentech's Biooncology Initiative
|
|
05 Dec 2001
|
FDA Advisory Committee Unanimously Recommends Approval of Breast Cancer Test to Select Candidates for Herceptin Therapy
|
|
30 Nov 2001
|
Genentech Invites Public to Listen to Webcast of December 10 Discussion of Rituxan Presentations at the American Society of Hematology Meeting
|
|
08 Nov 2001
|
Genentech Announces Stock Repurchase Program
|
|
07 Nov 2001
|
Genentech Announces Four Senior Appointments in Development and Product Operations
|
|
01 Nov 2001
|
Genentech and Novartis Update Xolair BLA Amendment Timeline
|
|
25 Oct 2001
|
National Cancer Institute (NCI) Trial Studying Genentech's Avastin in Advanced Kidney Cancer Reaches Pre-Specified Efficacy Endpoint Early
|
|
24 Oct 2001
|
No Verdict Reached in Genentech, City of Hope Contract Dispute
|
|
10 Oct 2001
|
Genentech Reports 34 Percent Increase in Product Sales for Third Quarter
|
|
09 Oct 2001
|
Genentech Named Among 100 Best Companies for Working Mothers
|
|
04 Oct 2001
|
Genentech and Xoma Update Xanelim BLA Filing Timing
|
|
26 Sep 2001
|
Genentech Announces October 10 Webcast Discussion of Earnings and Other Business Results
|
|
04 Sep 2001
|
FDA Approves Cathflo™ Activase® (Alteplase) To Restore Function To Central Venous Access Devices As Assessed By The Ability To Withdraw Blood
|
|
23 Aug 2001
|
ASSENT 3 Trial Shows Heart Attack Patients May Benefit From New Treatment Regimen: Clot-Buster Plus Low-Molecular-Weight Heparin
|
|
06 Aug 2001
|
Genentech Appoints Andrew C. Chan to Senior Director of Immunology
|
|
30 Jul 2001
|
Xanelim Shows Initial Positive Results in Second Pivotal Phase III Study
|
|
23 Jul 2001
|
Genentech Invites Public to Listen to Webcast of July 31 Discussion of Xanelim Phase III Results
|
|
16 Jul 2001
|
Genentech Foundation for Biomedical Sciences Awards $766,000 to Local Community Programs
|
|
11 Jul 2001
|
Genentech Reports 33 Percent Increase in Product Sales for Second Quarter
|
|
10 Jul 2001
|
FDA Issues Complete Response Letter for Xolair (Omalizumab)
|
|
28 Jun 2001
|
Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
|
|
21 Jun 2001
|
Xanelim in Pivotal Phase III Study Shows Initial Positive Results
|
|
14 Jun 2001
|
Genentech Invites Public to Listen to Webcast of June 21 Discussion of Xanelim Phase III Results
|
|
07 Jun 2001
|
Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech
|
|
30 May 2001
|
Genentech Names Thomas T. Thomas Treasurer
|
|
24 May 2001
|
Phase III Clinical Trials of Xanelim Humanized Monoclonal Antibody for Moderate-to-Severe Psoriasis Show Preliminary Positive Results
|
|
15 May 2001
|
Positive Investigational Data Presented On Rituxan Plus Fludarabine As Potential Front-Line Therapy For Chronic Lymphocytic Leukemia
|
|
15 May 2001
|
Genentech Appoints David Ebersman Senior Vice President, Product Operations
|
|
14 May 2001
|
Addition of Herceptin to Chemotherapy Demonstrates 50 Percent increase in Survival Benefit in Patients Selected by FISH
|
|
14 May 2001
|
FDA Approves Expanded Use of Rituxan for Treatment of Low-Grade Non-Hodgkin's Lymphoma (NHL)
|
|
14 May 2001
|
OSI Pharmaceuticals, Genentech and Roche Announce Clinical Data From Phase II Ovarian Cancer Trial of Tarceva (OSI-774)
|
|
12 May 2001
|
OSI Pharmaceuticals, Genentech and Roche Announce Interim Clinical Data From Phase II Cancer Studies of the Anti-EGFR Therapy Tarceva® (OSI-774)
|
|
04 May 2001
|
Genentech Wins Patent Dispute With GlaxoSmithKline
|
|
03 May 2001
|
Genentech Invites Public to View Webcast of May 10 Annual Meeting of Stockholders
|
|
01 May 2001
|
Oral Endothelin Receptor Antagonist Tracleer Meets Primary Endpoint In Pulmonary Arterial Hypertension Study
|
|
19 Apr 2001
|
Phase III Clinical Trial of Veletri for the Treatment of Acute Heart Failure Symptoms Does Not Meet Primary Efficacy Objective
|
|
12 Apr 2001
|
Genentech Reports 38 Percent Increase in Product Sales for First Quarter
|
|
10 Apr 2001
|
Genentech Appoints Kimberly Popovits Senior Vice President, Marketing and Sales, for CardioPulmonary and Specialty Markets
|
|
06 Apr 2001
|
Genentech and Biotech Celebrate 25 Years of Scientific and Medical Innovation
|
|
29 Mar 2001
|
Genentech Announces April 12 Webcast Discussion of Earnings and Other Business Results
|
|
20 Mar 2001
|
First Endothelin Receptor Antagonist Shows Positive Preliminary Results for Acute Heart Failure
|
|
16 Mar 2001
|
Genentech and Actelion Announce March 20 Webcast Discussion of Veletri (Tezosentan) RITZ-2 Trial Results
|
|
14 Mar 2001
|
Study Published in New England Journal of Medicine Demonstrates Herceptin with Chemotherapy Increases Median Survival in Women with Metastatic Breast Cancer
|
|
08 Mar 2001
|
Genentech And Novartis Update Expectations For FDA Review Of Xolair Biologics License Application
|
|
01 Mar 2001
|
Genentech Names Robert Garnick Senior Vice President, Regulatory, Quality And Compliance
|
|
13 Feb 2001
|
Genentech Invites Public to Listen to February 21, 2001 Webcast
|
|
12 Feb 2001
|
Phase III Trial of Intravenous Endothelin Receptor Antagonist Tezosentan for Acute Heart Failure Shows Positive Hemodynamic Results
|
|
18 Jan 2001
|
Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000
|
|
11 Jan 2001
|
Genentech Names John Whiting Vice President
|
|
09 Jan 2001
|
Genentech Announces January 18 Webcast Discussion of Earnings and Other Business Results
|
|
08 Jan 2001
|
OSI Pharmaceuticals, Genentech and Roche Team up to Deveolp and Commercialize OSI-774, OSI's Leading Cancer Drug to Develop and Commercialize OSI-774, OSI's Lead Cancer Drug
|
|
08 Jan 2001
|
COR, Schering-Plough, and Genentech Announce U.S. Collaboration for INTEGRILIN® (eptifibatide) Injection, TNKaseTM (Tenecteplase) and Activase® (Alteplase, Recombinant)
|
|
08 Jan 2001
|
Genentech and Alkermes to Expand Clinical Development of Nutropin Depot™
|
|
03 Jan 2001
|
Names Richard H. Scheller Senior Vice President, Research
|
|
19 Dec 2000
|
Genentech Names Claudia Estrin Vice President, Decision Support and Commercial Innovation
|
|
18 Dec 2000
|
Genentech Named One Of Fortune's "100 Best Companies To Work For In America"
|
|
12 Dec 2000
|
Actelion and Genentech Sign Licensing Agreement for Tracleer™ (Bosentan) in the U.S.
|
|
08 Dec 2000
|
Phase III Trials Underway Evaluating Herceptin In Early Stage Breast Cancer
|
|
05 Dec 2000
|
New Investigational Data Presented on Rituxan Plus Chemotherapy as Potential Front-Line Therapy
|
|
04 Dec 2000
|
Potential Survival Benefit Shown with Rituximab and CHOP Chemotherapy in Aggressive Non-Hodgkin's Lymphoma
|
|
11 Oct 2000
|
Genentech Reports 25 Percent Increase in Product Sales for Third Quarter
|
|
05 Oct 2000
|
Genentech Announces 2-For-1 Stock Split Effective October 17
|
|
02 Oct 2000
|
Genentech Announces Filing of Supplemental Biologic License Application
|
|
26 Sep 2000
|
Genentech Appoints Nagler to Vice President of Human Resources
|
|
11 Sep 2000
|
Genentech Launches Annual Community Relations Program to Boost Local Economic Development
|
|
08 Aug 2000
|
Genentech Appoints Joseph S. McCracken Vice President, Business Development
|
|
17 Jul 2000
|
Genentech Reports 15 Percent Increase in Product Sales for Second Quarter
|
|
13 Jul 2000
|
Genentech CEO Says Amgen/TKT Trial Outcome Not a Bellwether for Biotech
|
|
16 Jun 2000
|
Genentech Announces Phase II Trial of Experimental Anti-CD18 Antibody Did Not Meet Its Primary Objectives
|
|
05 Jun 2000
|
Genentech and Novartis Submit Application for FDA Approval of Anti-IgE Antibody
|
|
02 Jun 2000
|
FDA Approves New, Single-Injection Clot Buster TNKase (Tenecteplase) For Treatment Of Heart Attack
|
|
25 May 2000
|
Genentech Appoints Andrew Scherer Vice President, Engineering and Facilities
|
|
23 May 2000
|
Single Agent Herceptin Demonstrates 26 Percent Response Rate as Front-Line Metastatic Breast Cancer Therapy in Phase II Trial
|
|
23 May 2000
|
Preliminary Positive Phase II Results for Experimental Anti-VEGF Monoclonal Antibody with Chemotherapy in Lung Cancer Presented at ASCO
|
|
21 May 2000
|
Anti-VEGF Monoclonal Antibody with Chemotherapy Demonstrates Preliminary Positive Phase II Results in Colorectal Cancer
|
|
18 May 2000
|
Genentech Names Roy C. Hardiman Vice President, Corporate Law
|
|
16 May 2000
|
Genentech Appoints Myrtle Potter to EVP of Commercial Operations and COO
|
|
08 May 2000
|
ImmunoGen and Genentech Form Multi-Product Collaboration to Develop Tumor-Activated Prodrugs
|
|
04 May 2000
|
ImmunoGen and Genentech Sign Exclusive License Agreement
|
|
01 May 2000
|
Immunex and Genentech Moving Forward with Preclinical Development Program of TRAIL/Apo2L
|
|
25 Apr 2000
|
Genentech's Vacaville Facility Granted FDA Licensure
|
|
12 Apr 2000
|
Genentech Reports 21 Percent Increase in Product Sales for First Quarter
|
|
06 Apr 2000
|
Genentech Appoints Kraines Vice President of Finance
|
|
06 Apr 2000
|
Genentech Purchases Cell Culture Manufacturing Facility in Spain
|
|
23 Mar 2000
|
Offering by Roche of 17.3 Million Genentech Shares Priced at $163 Per Share
|
|
15 Mar 2000
|
Roche to Launch Offering of Up to 19 Million Genentech Shares
|
|
13 Mar 2000
|
Genentech Issues Important Drug Notification for Pulmozyme Due to Packing Defect
|
|
13 Mar 2000
|
Genentech Announces Clinical Trials Testing TNKase (Tenecteplase) with Leading Anti-Thrombotics for Treatment of Heart Attack
|
|
04 Mar 2000
|
Studies Show Investigational Compound May Help Improve Control of Asthma Exacerbations While Reducing the Need for Steroids and Rescue Medication
|
|
15 Feb 2000
|
Actelion and Genentech Sign Licensing Agreement for Tezosentan in the U.S.
|
|
20 Jan 2000
|
Genentech Reports 1999 Year-End Results
|
|
18 Jan 2000
|
Genentech to File Motion and Appeal to Maintain Injunction Against BTG
|
|
12 Jan 2000
|
Roche to Issue Exchangeable Bonds
|
|
23 Dec 1999
|
FDA Approves Nutropin Depot(TM), First Long-Acting Dosage Form of Recombinant Growth Hormone for Growth Hormone Deficiency in Children
|
|
21 Dec 1999
|
Genentech and Inspire to Collaborate on Respiratory Therapeutics
|
|
20 Dec 1999
|
Genentech and XOMA Announce Initiation of Anti-CD11A Phase III Clinical Trials for Psoriasis
|
|
20 Dec 1999
|
Genentech Named One of Fortune's "100 Best Companies to Work for in America"
|
|
17 Dec 1999
|
Phase III Anti-IgE Asthma Clinical Trials Show Positive Preliminary Results
|
|
16 Dec 1999
|
Genentech to Proceed With Phase III Trials of Experimental Anti-Angiogenesis Monoclonal Antibody
|
|
04 Dec 1999
|
New Data from Key Rituxan Clinical Studies Presented at 41st Annual Society of Hematology Meeting
|
|
02 Dec 1999
|
FDA Approves Efficacy Results for Spine Bone Mineral Density in Childhood-Onset Growth Hormone Deficient Adults
|
|
19 Nov 1999
|
University of California and Genentech Settle Patent Infringement Lawsuits
|
|
09 Nov 1999
|
COR Therapeutics, Schering-Plough and Genentech Announce Plans to Study INTEGRILIN -- eptifibatide -- Injection in Combination with TNKase -- tenecteplase -- in Heart Attack Patients
|
|
08 Nov 1999
|
Genentech and IDEC Pharmaceuticals to Receive 1999 Trailblazers Award from Cure for Lymphoma Foundation
|
|
27 Oct 1999
|
Genentech and Chairman/CEO Levinson to Receive National Breast Cancer Coalition's Corporate Leadership Award
|
|
22 Oct 1999
|
Genentech 2-For-1 Stock Split Effective on October 29
|
|
20 Oct 1999
|
Secondary Offering by Roche of 20 Million Genentech Shares Priced at $143.50
|
|
08 Oct 1999
|
SEC Registration Filed for Genentech Public Offering
|
|
07 Oct 1999
|
Roche To Publicly Sell 20 Million Genentech Shares, Genentech Board Approves 2-For-1 Stock Split
|
|
29 Sep 1999
|
Genentech Chairman/CEO Arthur Levinson Receives Irvington Institute's Corporate Leadership Award
|
|
27 Sep 1999
|
Genentech Appoints Sulzbach Vice President, Information Resources
|
|
22 Sep 1999
|
Genentech Names Levinson as New Board Chair and Announces Appointment of Two New Directors
|
|
13 Sep 1999
|
Genentech Launches Annual Program to Boost Economic Development of Its Hometown of 23 Years
|
|
01 Sep 1999
|
Genentech Named Among 100 Best Companies For Working Mothers
|
|
24 Aug 1999
|
Genentech Appoints James Panek, Senior Vice President, Product Operations
|
|
24 Aug 1999
|
Genentech Appoints Laura Leber Vice President, Corporate Communications
|
|
19 Aug 1999
|
XOMA Announces Expansion of Genentech Collaboration in hu1124 to Include Organ Transplant Rejection
|
|
02 Aug 1999
|
Genentech Submits Application for FDA Approval of Tenecteplase (TNK-tPA)
|
|
19 Jul 1999
|
Genentech, Inc. Announces Public Offering of 20 Million Shares Under New NYSE Trading Symbol, DNA
|
|
12 Jul 1999
|
Genentech Reports 1999 Second Quarter Results
|
|
08 Jul 1999
|
Unique Program Allows Previous Genentech Shareholders to be Included in Genentech Public Offering
|
|
01 Jul 1999
|
Genentech Appoints Diane Parks Vice President of Marketing
|
|
30 Jun 1999
|
Genentech Scientists Receive Distinguished Inventor Award
|
|
28 Jun 1999
|
Genentech and Alkermes Announce the Submission of a New Drug Application with the FDA for Nutropin Depot
|
|
14 Jun 1999
|
Roche Exercises Option to Redeem Genentech Shares
|
|
14 Jun 1999
|
SEC Registration Filed for Genentech Public Offering
|
|
13 Jun 1999
|
Phase III Clinical Trial Shows Promising Results of Nutropin Depot
|
|
08 Jun 1999
|
Genentech and Immunex Announce Patent License Agreement for Immunoadhesin Technology for ENBREL
|
|
07 Jun 1999
|
Study Shows Simpler Procedures Employed by Industry-Sponsored Heart Attack Registry Are Comparable to More Complex Government Program
|
|
02 Jun 1999
|
Genentech to Remain Independent Company, Roche Intends to Exercise Its Call Option and Publicly Reissue Genentech Shares
|
|
02 Jun 1999
|
No Verdict Reached in Genentech, University of California Patent Infringement Case
|
|
01 Jun 1999
|
Immunex Corporation and Genentech, Inc. Join Forces To Develop TRAIL/Apo2L in Cancer
|
|
19 May 1999
|
Genentech Confirms Growth Hormone Research Performed Independently; Seeburg Testimony is False
|
|
15 May 1999
|
Follow-Up Data Shows Improvement in Overall Survival in Metastatic Breast Cancer Patients Treated with Herceptin, Plus Chemotherapy
|
|
14 May 1999
|
Phase III Trial with Anti-IgE Shows Positive Results in Treating Seasonal Allergic Rhinitis
|
|
15 Apr 1999
|
XOMA and Genentech Extend hu1124 (Anti-CD11a) Collaboration Through Phase III
|
|
14 Apr 1999
|
Genentech Confirms Settlement Agreement with U.S. Government
|
|
12 Apr 1999
|
Genentech Reports 1999 First Quarter Results
|
|
09 Apr 1999
|
Genentech Discussing Settlement with U.S. Government
|
|
08 Apr 1999
|
Phase III Trial With Nerve Growth Factor Did Not Reach Its Goal
|
|
09 Mar 1999
|
International Trial Shows Promising Results for Genentech's New Clot Buster Compared with Activase
|
|
22 Feb 1999
|
Genentech Names Ebersman Vice President
|
|
18 Feb 1999
|
Preliminary Phase II Trial Results with Experimental Vascular Endothelial Growth Factor in Patients with Coronary Artery Disease are Disappointing
|
|
09 Feb 1999
|
Genentech Issued New t-PA Patent and Files Patent Infringement Suit Against Centocor's Thrombolytic Agent
|
|
29 Jan 1999
|
Schwarz Pharma AG and Genentech enter into a collaboration for two growth hormone products
|
|
21 Jan 1999
|
Genentech Reports 41 Percent Increase in Year-End Net Income
|
|
12 Jan 1999
|
Genentech Corporate Child Care Center Celebrates 10 Years
|
|
21 Dec 1998
|
Genentech Named One of Fortune's 100 Best Companies to Work For in America
|
|
10 Dec 1998
|
Genentech Appoints Dilly Vice President of Medical Affairs
|
|
08 Dec 1998
|
Rituxan Follow-Up Data Shows 28 Percent of Responders Still in Remission
|
|
09 Nov 1998
|
New Investigational Data Show Monoclonal Antibody to IgE May Reduce Seasonal Allergy Symptoms
|
|
03 Nov 1998
|
Genentech Names Barta Vice President, Quality
|
|
23 Oct 1998
|
Genentech Dedicates $250 Million Vacaville Facility
|
|
22 Oct 1998
|
Genentech and Alkermes Announce Positive Preliminary Results of Phase III Clinical Trial of Nutropin Depot®
|
|
14 Oct 1998
|
Genentech Reports Third Quarter Results
|
|
25 Sep 1998
|
Biotechnology Breakthrough In Breast Cancer Wins FDA Approval
|
|
14 Sep 1998
|
Genentech and South San Francisco Celebrate Six-Year Anniversary of Community Program
|
|
02 Sep 1998
|
FDA Advisory Committee Recommends Approval of First Monoclonal Antibody for Metastatic Breast Cancer
|
|
17 Aug 1998
|
Pivotal Clinical Trial of First Monoclonal Antibody
|
|
20 Jul 1998
|
U.S. Stroke Study Halted Due to Lack of Clinical Benefit Observed in Patients Treated After Three Hours
|
|
14 Jul 1998
|
Genentech Reports 1998 2nd Quarter Results
|
|
06 Jul 1998
|
Roche And Genentech Sign Licensing Agreement For Herceptin
|
|
29 Jun 1998
|
Novo Nordisk and Genentech Settle Long Term Dispute over Patents
|
|
25 Jun 1998
|
Genentech Names Johnston Vice President, Intellectual Property
|
|
18 May 1998
|
Phase II Pilot Study of Rituxan with Chemotherapy Showed 97% Response Rate in Type of Non-Hodgkin's Lymphoma
|
|
18 May 1998
|
Genentech Names Moore Vice President of Government Affairs
|
|
18 May 1998
|
Results of Phase III Studies Announced for HER2 Antibody, Herceptin
|
|
05 May 1998
|
Genentech Names Dennis Henner and Stephen Juelsgaard to Senior Vice Presidents
|
|
04 May 1998
|
Genentech Submits Application for FDA Approval of HER2 Antibody, Herceptin
|
|
14 Apr 1998
|
Genentech Reports 1998 First Quarter Results - 30 Percent Earnings Increase
|
|
13 Apr 1998
|
Genentech Names Moore New Head of Government Affairs Office
|
|
31 Mar 1998
|
Genentech Receives Fast Track Product Designation for Herceptin By FDA
|
|
17 Mar 1998
|
Genentech Files Patent Infringement Suit Against Centocor's Thrombolytic Agent
|
|
02 Mar 1998
|
Pulmozyme Receives FDA Approval for Labeling Change
|
|
02 Mar 1998
|
Genentech and Dako Announce Collaboration on HER2 Diagnostic Kit In Breast Cancer
|
|
28 Jan 1998
|
Vice President Gore To Visit Genentech
|
|
22 Jan 1998
|
Genentech's Year-End Results On Track
|
|
08 Jan 1998
|
Sumitomo Pharmaceuticals and Genentech Enter Into Collaboration
|
|
08 Jan 1998
|
Pharmacia & Upjohn Acquires Rights from Genentech for Thrombopoietin (TPO)
|
|
19 Dec 1997
|
Genentech Announces Phase III Investigational Trial Results
|
|
18 Dec 1997
|
Genentech Wins FDA Clearance of its Ready-To-Use Nutropin AQ
|
|
18 Dec 1997
|
LeukoSite and Genentech Enter Collaboration
|
|
17 Dec 1997
|
Genentech Wins Clearance of Nutropin for Growth Hormone Deficiency
|
|
16 Dec 1997
|
New Drug for Non-Hodgkin's Lymphoma Available Now
|
|
04 Dec 1997
|
Alteon and Genentech to Collaborate on Therapy for Diabetic Complications
|
|
26 Nov 1997
|
First New Drug for Non-Hodgkin's Lymphoma in Decade Receives FDA Clearance for Marketing
|
|
24 Nov 1997
|
Genentech and Alkermes Announce Plans to Advance Prolease®, Human Growth Hormone to Phase III Clinical Trials
|
|
14 Oct 1997
|
Genentech Reports 1997 Third Quarter Results
|
|
19 Sep 1997
|
Anti-IgE Monoclonal Antibody Progresses to Phase III Trials in Asthma
|
|
05 Sep 1997
|
Genentech Discontinues IGF-I Drug Development Effort in Diabetes
|
|
04 Sep 1997
|
Health Care Pioneers Reinforce Commitment to Improving Public Health
|
|
26 Aug 1997
|
New Clot-Dissolving Agent Shows Promise
|
|
25 Jul 1997
|
FDA Advisory Committee Recommends Clearance for Cancer Treatment
|
|
15 Jul 1997
|
Genentech Reports 1997 Second Quarter Results
|
|
24 Jun 1997
|
Genentech Creates New Strand of DNA
|
|
16 Jun 1997
|
Genentech and South San Francisco Celebrate Community Program
|
|
15 May 1997
|
Genentech Focuses On Cancer as it Launches BioOncology Initiative
|
|
05 May 1997
|
Genentech Announces Plans to Study TNK-tPA in Phase III
|
|
01 May 1997
|
Genentech Appoints Lars Barfod Vice President of Marketing
|
|
15 Apr 1997
|
Genentech Reports 1997 First Quarter Results
|
|
09 Apr 1997
|
Genentech is Granted Patents for Recombinant Factor VIII
|
|
02 Apr 1997
|
Scios Suspends Development of AURICULIN
|
|
01 Apr 1997
|
FDA Clears Genentech's Nutropin AQ
|
|
20 Mar 1997
|
Bill Young Appointed COO of Genentech
|
|
19 Mar 1997
|
Leader in Oncology to Head Genentech's Molecular Oncology Department
|
|
17 Mar 1997
|
Comparison of Two Heart Attack Drugs Fails to Prove Primary Endpoint
|
|
07 Mar 1997
|
Genentech Appoints Two New Vice Presidents
|
|
03 Mar 1997
|
IDEC, Genentech & Roche Submit Applications for Approval of IDEC-C2B8
|
|
21 Jan 1997
|
Genentech Reports 1996 Year-End Results
|
|
09 Jan 1997
|
Roche and GNE Announce Agreement for Roferon-A
|
|
30 Dec 1996
|
FDA Clears Genentech's Nutropin Human Growth Hormone
|
|
13 Dec 1996
|
Genentech Names Dick Munro as New Board Chair
|
|
12 Dec 1996
|
Genentech Founder Swanson Retires as Board Chair
|
|
10 Dec 1996
|
FDA Advisory Committee Recommends Nutropin
|
|
09 Dec 1996
|
IDEC Pharmaceuticals and Genentech Announce Positive Final Results
|
|
03 Dec 1996
|
Genentech and Baxter to Collaborate
|
|
02 Dec 1996
|
Pulmozyme Receives Marketing Clearance for Use in Advanced Cystic Fibrosis Patients
|
|
21 Oct 1996
|
Genentech Reports 1996 Third Quarter Results
|
|
15 Oct 1996
|
Genentech Advances Study of Nerve Growth Factor
|
|
09 Oct 1996
|
FDA Advisory Committee Recommends Pulmozyme
|
|
30 Sep 1996
|
Genentech Files Amended Complaint Against Novo Nordisk
|
|
26 Sep 1996
|
Delaware Court Approves Settlement
|
|
15 Jul 1996
|
New Senior Vice Presidents
|
|
15 Jul 1996
|
Genentech Employees Take Another $50,000 Shopping Spree In Downtown South San Francisco, The Company's Hometown For 20 Years
|
|
15 Jul 1996
|
Genentech Reports 1996 Second Quarter Results
|
|
09 Jul 1996
|
Tanox Biosystems and Genentech Settle Lawsuits
|
|
27 Jun 1996
|
Genentech Granted Preliminary Injunction
|
|
18 Jun 1996
|
Activase Cleared by FDA for U.S. Marketing
|
|
07 Jun 1996
|
Genentech Discontinues Pursuit of Actimmune for Renal Cell Carcinoma
|
|
06 Jun 1996
|
FDA Advisory Committee Recommends Approval of Activase
|
|
28 May 1996
|
Patent Infringement Suit Filed Against Boehringer
|
|
23 May 1996
|
Genentech Donates $25,000 To Solano Community College
|
|
30 Apr 1996
|
Genentech Names Robert Arathoon to VP of Process Science
|
|
29 Apr 1996
|
Genentech Names Henner as Head of Research
|
|
22 Apr 1996
|
Genentech and XOMA Agree to Develop Jointly Anti-CD11a
|
|
16 Apr 1996
|
Genentech Reports 1996 First Quarter Results
|
|
08 Apr 1996
|
Appeals Court Upholds Preliminary Injunction Prohibiting Sales of Biotechnology General's Growth Hormone Product
|
|
04 Apr 1996
|
Biotechnology Pioneer Genentech Turns 20
|
|
04 Apr 1996
|
Genentech Licenses Worldwide Rights From Washington University for GDNF Homologue, Neurturin
|
|
02 Apr 1996
|
Genentech Wins Second Major Biotechnology Patent Dispute In Japan
|
|
19 Mar 1996
|
Genentech Submits Product License Application for Activase
|
|
20 Feb 1996
|
Genentech Names Cynthia Ladd VP, Corporate Law
|
|
20 Feb 1996
|
Genentech Announces Creation of Genenvax to Develop AIDS Vaccine
|
|
18 Jan 1996
|
Genentech Posts Strong Year-End Results
|
|
04 Jan 1996
|
Levinson Appoints McLaughlin and Young as Executive Vice Presidents
|
|
03 Jan 1996
|
FDA Grants Genentech Clearance to Market Nutropin AQ
|
|
18 Dec 1995
|
Patent Claims Upheld for Genentech's t-PA in Europe
|
|
17 Nov 1995
|
Brewer Resigns as Genentech's Senior VP of Sales & Marketing
|
|
25 Oct 1995
|
Genentech Stockholders Approve Roche's Extended Buyout Option
|
|
23 Oct 1995
|
Genentech Reports 20 Percent Increase in Earnings for Third Quarter 1995
|
|
05 Oct 1995
|
Genentech's Blood Platelet Factor (TPO) Enters the Clinic as Phase I Trial Begins
|
|
04 Oct 1995
|
Genentech Submits NDA for Nutropin in Turner's Syndrome
|
|
03 Oct 1995
|
Ed Jennings Cleared of All Charges
|
|
13 Sep 1995
|
Genentech Completes Negotiations, Purchases Land For New Manufacturing Facility in Vacaville, CA
|
|
21 Aug 1995
|
Genentech Receives Favorable Ruling on Process Patent Applicaiton for Recombinant Human Factor VIII:C
|
|
11 Aug 1995
|
Genentech Granted Preliminary Injunction Prohibiting Sale of Bio-Technology General (BTG) Human Growth Hormone Product
|
|
18 Jul 1995
|
Genentech Reports 1995 Second Quarter Results
|
|
10 Jul 1995
|
Review Board Recommends Termination of Phase III Study of Pulmozyme in Chronic Obstructive Pulmonary Disease
|
|
10 Jul 1995
|
Genentech Board Names Levinson President & CEO
|
|
28 Jun 1995
|
Judge Grants Genentech's Request for Preliminary Injunction Prohibiting Sale of Novo Nordisk's Growth Hormone
|
|
25 May 1995
|
Genentech and Roche Change Form of Transaction to Accommodate New Schedule for Stockholder Vote
|
|
12 Apr 1995
|
Genentech Reports Strong 1995 First Quarter Results
|
|
03 Apr 1995
|
Accelerated Infusion Regimen of Activase Cleared by FDA for U.S. Marketing
|
|
03 Mar 1995
|
Genentech and IDEC Pharmaceuticals to Collaborate on Anti-CD20 Monoclonal Antibody for B-Cell Lymphomas
|
|
19 Jan 1995
|
Genentech Reports 1994 Fourth Quarter Results
|
|
17 Jan 1995
|
ITC Votes Not to Review Judge's Decision
|
|
05 Jan 1995
|
Genentech and Lilly Reach Settlement
|
|
03 Jan 1995
|
Genentech and Scios Nova Enter Into Agreement for Development of Acute Kidney Failure Treatment
|
|
30 Nov 1994
|
Judge Finds Growth Hormone Patent Infringement by Novo-Nordisk and BTG; Recommends Dismissal of Complaint On Technicality
|
|
24 Nov 1994
|
Study Reaffirms Benefits of Activase t-PA
|
|
31 Oct 1994
|
Genentech Locates Major New Facility in Vacaville, CA
|
|
18 Oct 1994
|
Genentech Reports 1994 Third Quarter Results
|
|
12 Sep 1994
|
Genentech Names Louis J. Lavigne, Jr. Senior Vice President and Stephen Juelsgaard Vice President and General Counsel
|
|
25 Aug 1994
|
Genentech Names Dennis Henner and Bryan Lawlis Vice Presidents
|
|
05 Aug 1994
|
Genentech Opposes Recommendations to Make Growth Hormone a Scheduled Drug
|
|
04 Aug 1994
|
Genentech Employee Indicted on Charges of Violating Medicare/Medicaid Anti-Remuneration Laws as a Result of Federal Investigation in Minnesota
|
|
18 Jul 1994
|
Genentech Reports 1994 Second Quarter Results
|
|
28 Jun 1994
|
Genentech Responds to Ruling Regarding t-PA Patent Infringement by Genetics Institute
|
|
16 Jun 1994
|
Local Elementary School Students 'Go To Town' with Genentech Employees in South San Francisco
|
|
15 Jun 1994
|
Genentech Reports Discovery of New Blood Platelet Factor
|
|
10 Jun 1994
|
FDA's Cardio-Renal Advisory Committee Unanimously Recommends Accelerated Activase t-PA Label Change by FDA
|
|
07 Jun 1994
|
Genentech Names Polly Moore and Robert Garnick to Vice Presidents
|
|
25 May 1994
|
Genentech Extends Benefits Coverage to Same-Sex Domestic Partners
|
|
21 Apr 1994
|
Genentech Files Suit Against Centocor
|
|
15 Apr 1994
|
Genentech Reports 1994 First Quarter Results
|
|
11 Apr 1994
|
Pulmozyme Introduced in Ireland
|
|
04 Apr 1994
|
Genentech to Provide Growth Hormone Products Through PCS Pharmacy Network
|
|
04 Apr 1994
|
Pulmozyme Phase II Clinical Study Completed in Hospitalized Chronic Bronchitis Patients
|
|
08 Mar 1994
|
FDA Grants Genentech License to Market Nutropin for Growth Hormone Deficiency in Children
|
|
28 Feb 1994
|
Genentech Receives U.S. Patent for Transforming Growth Factor Beta (TGF)
|
|
11 Feb 1994
|
Genentech Begins Construction of $58 Million Laboratory Facility in South San Francisco
|
|
21 Jan 1994
|
Genentech Files Suit against Tanox Biosystems
|
|
19 Jan 1994
|
Settlement Reached in Factor VIII Litigation Involving Genentech, Miles, The Scripps Research Institute and Rhone-Poulenc Rorer
|
|
19 Jan 1994
|
Genentech Reports 1993 Fourth Quarter And Year End Results
|
|
07 Jan 1994
|
Pulmozyme Becomes Available to Cystic Fibrosis Patients
|
|
30 Dec 1993
|
FDA Grants Genentech License to Market Pulmozyme
|
|
18 Nov 1993
|
J. Beers Named General Manager of Genentech Canada, Inc.
|
|
17 Nov 1993
|
Genentech Receives FDA Approval to Market Nutropin for Growth Failure Due to Chronic Renal Insufficiency
|
|
25 Oct 1993
|
FDA Advisory Committee Unanimously Recommends Approval for Nutropin as Treatment for Growth Failure in Children with Chronic Renal Insufficiency
|
|
19 Oct 1993
|
Genentech Unveils $10 Million Program for High School Biology Teachers
|
|
14 Oct 1993
|
Genentech Reports Third Quarter Results
|
|
30 Sep 1993
|
Study Shows Alteplase t-PA Significantly Reduces Death Up To 12 Hours After Heart Attack Begins
|
|
03 Sep 1993
|
Activase Regains Marketshare
|
|
20 Aug 1993
|
STILE Study for Peripheral Arterial Occlusion Discontinued
|
|
09 Aug 1993
|
FDA Advisory Committee Unanimously Recommends Pulmozyme (DNase) for Approval as Cystic Fibrosis Treatment
|
|
29 Jul 1993
|
Genentech Granted Permanent Injunction in Wellcome Litigation Over t-PA Patents
|
|
14 Jul 1993
|
Genentech Reports Second Quarter Results
|
|
22 Jun 1993
|
Genentech Issued Pioneering Basic Processes Patent; Files Suit Against Lilly for Infringement
|
|
14 Jun 1993
|
Bio Holds First Board Meeting, Genentech CEO Elected Chairman
|
|
30 Apr 1993
|
41,000 Patient Gusto Trial Shows Activase t-PA Most Effective Clot-Buster to Save Lives of Heart Attack Patients
|
|
16 Apr 1993
|
Genentech Reports First Quarter Results
|
|
15 Apr 1993
|
Genentech Joins Coalition in Favor of Biodiversity Treaty
|
|
30 Mar 1993
|
Genentech Files Regulatory Applications to Market Pulmozyme (dornase alfa) DNase for Cystic Fibrosis in the United States, Canada, Europe
|
|
28 Mar 1993
|
Press Statement: Government-Imposed Price Controls Would Strangle Investment and Raise Health Care Costs
|
|
16 Mar 1993
|
Genentech Files Complaint with International Trade Commission to Enforce Growth Hormone Patents
|
|
03 Mar 1993
|
Genentech Announces Collaboration with GenVec to Develop Gene Therapy for Cystic Fibrosis
|
|
10 Feb 1993
|
Genentech French Patent Partially Revoked
|
|
20 Jan 1993
|
Genentech Reports Fourth Quarter and Year End Results
|
|
10 Dec 1992
|
Genentech Names Kurt Kopp to Head European Organization
|
|
09 Dec 1992
|
Genentech Receives U.S. Patent for Recombinant Human Nerve Growth Factor
|
|
02 Dec 1992
|
Pulmozyne(TM)(rhDNase) III Clinical Study Completed in Cystic Fibrosis
|
|
23 Oct 1992
|
Genentech Opens World's Largest Biotechnology Research Facility
|
|
15 Oct 1992
|
Genentech Reports Third Quarter Results
|
|
10 Sep 1992
|
Genentech Elects Linda Fayne Levinson To Board Of Directors
|
|
03 Sep 1992
|
Study Shows Altepase t-PA Significantly Reduces Mortality Up to 12 Hours After Heart Attack Begins
|
|
17 Jul 1992
|
Court Rules in Favor of Genentech in t-PA Patent Dispute
|
|
16 Jul 1992
|
Genentech Reports Second Quarter Results
|
|
15 Jul 1992
|
Xenova Receives Additional Equity Investment from Genentech, Inc.
|
|
08 Jun 1992
|
Genentech Secures European Patent for t-PA
|
|
14 Apr 1992
|
Genentech Reports First Quarter Results
|
|
31 Mar 1992
|
Genentech Names Gregory Baird Vice President of Corporate Communications
|
|
03 Mar 1992
|
Genentech Enters International Commercial Development and Marketing Agreement with Roche for DNase
|
|
16 Jan 1992
|
Genentech Reports Fourth Quarter and Year End Results
|
|
15 Jan 1992
|
Tularik Inc. Formed to Pursue Novel Biopharmaceutical Approach
|
|
10 Dec 1991
|
Wellcome and Sandoz Out-License Genentech Monoclonal Antibidody Patent
|
|
29 Oct 1991
|
Genentech Announces Auction of Vitamin C Concern
|
|
28 Oct 1991
|
Genentech Wins First Major Japanese Biotechnology Patent Case
|
|
16 Oct 1991
|
Genentech Announces Third Quarter Earnings
|
|
23 Sep 1991
|
Incyte And Genentech To Develop Drug For Treating Septic Shock
|
|
09 Sep 1991
|
Genentech and Xenova Announce New $20 Million Agreement
|
|
31 Jul 1991
|
Genentech Promotes Marty Glick to Vice President and Treasurer
|
|
17 Jul 1991
|
Genentech Reports Second Quarter Results
|
|
18 Jun 1991
|
Roche and Genentech Reach Agreement Over Human Growth Hormone Patent Dispute
|
|
06 Jun 1991
|
Genentech's t-PA Launched in Japan
|
|
18 Apr 1991
|
Genentech Announces First Quarter Results
|
|
05 Apr 1991
|
Genentech to Test Potential Therapy for Breast and Ovarian Cancers
|
|
21 Mar 1991
|
New gp120 AIDS Vaccine Enters NIAID Clinical Trials
|
|
03 Mar 1991
|
ISIS-3 Results Controversial and Inconclusive for U.S. Practice; T-PA Used in ISIS-3 Study Not Genentech's Product
|
|
28 Feb 1991
|
SmithKline to Stop Misleading ISIS-3 Ads
|
|
28 Feb 1991
|
Judge Requires Beecham To Abide By Court Promises Concerning ISIS-3 Ads
|
|
25 Feb 1991
|
Genentech Seeks Federal Court Order to Stop Beecham's False Advertising of Heart Attack Drugs
|
|
29 Jan 1991
|
FDA Grants Genentech Orphan Drug Status for DNase, a Potential Cystic Fibrosis Treatment
|
|
22 Jan 1991
|
Telios Pharmaceuticals and Genentech to Develop Anti-Clotting Drug
|
|
21 Jan 1991
|
Xenova and Genentech Expand Their Research and Development Collaboration
|
|
17 Jan 1991
|
Genentech Reports Fourth Quarter Earnings
|
|
07 Jan 1991
|
Genentech and Glycomed Announce Pact to Develop Carbohydrate-Based Therapeutics
|
|
21 Dec 1990
|
Genentech Granted Product License for Interferon Gamma-1B
|
|
21 Dec 1990
|
HHS News U.S. Department of Health and Human Services
|
|
17 Dec 1990
|
Genentech to Broadly License Key Monoclonal Antibody Patent
|
|
07 Dec 1990
|
Genentech Reaches an Agreement to Settle Class Action Litigation
|
|
27 Nov 1990
|
Study Begins to Test gp120 as a Potential Immune System Booster in HIV Infection
|
|
23 Oct 1990
|
Genentech Announces Third Quarter Results
|
|
12 Oct 1990
|
Genentech to Build $75 Million Research Center
|
|
20 Sep 1990
|
European Co-operative Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA)
|
|
07 Sep 1990
|
Genentech and Roche Merger Transaction Completed
|
|
31 Aug 1990
|
Roche and Genentech to Complete Merger Transaction On or About September 7
|
|
15 Aug 1990
|
Genentech and Abott Settle Litigation Over t-PA Patents
|
|
07 Aug 1990
|
Genentech Promotes Marty Glick to Treasurer
|
|
07 Aug 1990
|
Genentech Promotes Arthur D. Levinson to Vice President of Research
|
|
06 Aug 1990
|
Genentech and Roche Certify Substantial Compliance with FTC Request
|
|
13 Jul 1990
|
Genentech Reports Second Quarter Results
|
|
08 Jun 1990
|
Genentech Stockholders Approve Roche Agreement
|
|
06 Jun 1990
|
FDA Approves t-PA for Pulmonary Embolism
|
|
06 Jun 1990
|
Motion to Enjoin Vote at Genentech Stockholder Meeting Denied
|
|
01 Jun 1990
|
Genentech Research on Protection of Chimpanzees from HIV Infection to be Published
|
|
29 May 1990
|
Genentech Announces Potential Therapy for Cystic Fibrosis
|
|
23 May 1990
|
Genentech Receives Important Process Patent For Gamma Interferon
|
|
03 May 1990
|
Genentech Issues Proxy on Roche Merger; Annual Meeting Set for June 8
|
|
25 Apr 1990
|
Genentech Reports First Quarter Results
|
|
06 Apr 1990
|
Genentech Wins Key t-PA Patent Cases in U.S. Federal Court
|
|
29 Mar 1990
|
Roche-Genentech Transaction Passes Exon-Florio Review
|
|
23 Mar 1990
|
Federal Trade Commission Requests More Information on Genentech-Roche Merger
|
|
08 Mar 1990
|
New Trial Results Inconclusive for U.S. Practice; Role of Heparin in Gissi-2 Questioned
|
|
28 Feb 1990
|
Genentech Begins Clinical Trials of Relaxin
|
|
02 Feb 1990
|
Genentech and Roche Holding LTD Form Pioneering Relationship; Roche to Own 60 Percent of an Independent Genentech
|
|
29 Jan 1990
|
Physicians Choose Activase as Preferred Heart Attack Treatment for Themselves
|
|
18 Jan 1990
|
Biogen and Genentech Enter Into Cross-License Agreement for Gamma Interferon in The United States
|
|
18 Jan 1990
|
Revised Development Plans Announced for CD4-based Products, Potential AIDS Therapeutics
|
|
17 Jan 1990
|
Genentech Fourth Quarter Revenues Up 24 Percent; 1989 Revenues Top $400 Million
|
|
09 Jan 1990
|
Genentech Surpasses 1989 Product Sales Goals
|
|
03 Jan 1990
|
Genentech Acquires Full Ownership of Canadian Operation
|
|
02 Jan 1990
|
Genentech Files FDA Application to Market Gamma Interferon in The United States
|
|
12 Dec 1989
|
TGF-beta Patent Issued December 12, 1989
|
|
30 Nov 1989
|
Genentech Sponsors Programs for Pharmacists "Building A New Pharmacopeia" Premieres at ASHP
|
|
10 Nov 1989
|
Genentech Appoints Richard Brewer Vice President- Marketing
|
|
10 Nov 1989
|
Genentech Appoints Gary Lyons Vice President -- Business Development
|
|
30 Oct 1989
|
Competitors Merge Marketing Strength to Co-Promote t-PA, Blood-Clot-Dissolving Agent, in Germany
|
|
24 Oct 1989
|
Genentech Third Quarter Profits Higher
|
|
18 Sep 1989
|
Genentech Receives Third Patent for Gamma Interferon
|
|
14 Sep 1989
|
Genentech Begins Clinical Trials of Insulin-Like Growth Factor
|
|
30 Aug 1989
|
Genentech Awards First Scientific Fellowship to David Goeddel
|
|
29 Aug 1989
|
Genentech Appoints M. David MacFarlane Vice President -- Regulatory Affairs
|
|
21 Aug 1989
|
Genentech rCD4 Partnership Raises $72.5 Million
|
|
11 Aug 1989
|
Genentech Promotes Murphy and Adds Rogers to Public Relations Staff
|
|
01 Aug 1989
|
Genentech Receives Additional United States Patent for t-PA
|
|
18 Jul 1989
|
Genentech Reports Second Quarter Earnings
|
|
06 Jun 1989
|
Genentech Expands CD4 Clinical Trials for AIDS
|
|
24 May 1989
|
Genentech Appoints David Beier Vice President - Government Affairs
|
|
11 May 1989
|
Genentech Opens Corporate Day Care Center
|
|
19 Apr 1989
|
Genentech Reports First Quarter Earnings and Increase in Activase Sales
|
|
13 Apr 1989
|
Genentech Scientists Share 1989 Investor of the Year Award
|
|
21 Mar 1989
|
Cross-Licensing Agreement Reached on Factor VIII Genetically Engineered Clotting Agent for Hemopheliacs
|
|
27 Feb 1989
|
FDA Approves Reduced Mortality Claim for Heart Attack Drug
|
|
16 Feb 1989
|
Genentech Anounces Activase Co-Promotion Agreement
|
|
31 Jan 1989
|
Genentech Will Not Appeal British t-PA Patent Case
|
|
25 Jan 1989
|
Genentech Reports 1988 Financial Results
|
|
10 Jan 1989
|
Genentech Meets Sales Forecast and Announces Two Collaborative Agreements
|
|
09 Jan 1989
|
Genentech, Cal Bio Announce Neonatology Product Agreement
|
|
12 Dec 1988
|
Genentech Forecasts 1988 Results
|
|
08 Dec 1988
|
Ralph Snyderman, Genentech VP Named Chancellor at Duke University Medical School
|
|
09 Nov 1988
|
New Drug Application For t-PA Filed in Japan
|
|
31 Oct 1988
|
British Court of Appeals Rules in t-PA Patent Case
|
|
21 Oct 1988
|
Genentech Reports Results For Third Quarter
|
|
14 Oct 1988
|
Genentech Reports Shareholder Suits Filed
|
|
27 Sep 1988
|
Genentech Sees Quarterly Earnings Flat With Last Year
|
|
23 Aug 1988
|
Genentech Receives Second t-PA Patent in the United States
|
|
05 Aug 1988
|
Genentech Wins Growth Hormone Patent Suit
|
|
14 Jul 1988
|
Genentech Reports Increased Earnings, Sales in Second Quarter
|
|
05 Jul 1988
|
Axel Ullrich, Genentech Staff Scientist, Named Director of Max Planck Institute
|
|
23 Jun 1988
|
Free Heart Drug To Needy, Uninsured Patients
|
|
21 Jun 1988
|
Genentech Receives Broad t-PA Patent in the United States
|
|
11 May 1988
|
Genentech Appoints Two Vice Presidents
|
|
21 Apr 1988
|
Genentech Adopts Preferred Share Rights Purchase Plan
|
|
18 Apr 1988
|
Genentech Reports First Quarter Earnings
|
|
07 Apr 1988
|
Genentech Creates Foundation to Fund Basic Biotechnology Research
|
|
03 Mar 1988
|
Genentech Announces New VP of Sales
|
|
24 Feb 1988
|
Genentech Names Three Vice Presidents
|
|
24 Feb 1988
|
Genentech Stock to be Listed on NYSE March 2
|
|
22 Feb 1988
|
Genentech Elects New Director to Its Board
|
|
21 Jan 1988
|
Genentech Reports Significant Increase in 1987 Financial Results
|
|
11 Jan 1988
|
Genentech Announces Product Sales and NYSE Listing
|
|
13 Nov 1987
|
T-PA Approved in Canada
|
|
13 Nov 1987
|
Licensing of Activase Marks New Era in Treating Heart Attacks
|
|
03 Nov 1987
|
Genentech's Patent on Basic Recombinant DNA Technology Issues in The United States
|
|
02 Nov 1987
|
Genentech Reports Third Quarter Results
|
|
14 Oct 1987
|
Genentech Appoints Two Vice Presidents
|
|
13 Oct 1987
|
T-PA Approved in West Germany
|
|
31 Aug 1987
|
T-PA Approved in South Korea
|
|
24 Aug 1987
|
Genentech Files Patent Suit on t-PA
|
|
07 Aug 1987
|
T-PA Approved in Austria
|
|
21 Jul 1987
|
Genentech Reports Second Quarter Results
|
|
07 Jul 1987
|
Britain's High Court Rules on t-PA Patent Dispute
|
|
01 Jul 1987
|
Mitsubishi Chemical Industries and Genentech Agree to Commercialize Research Products
|
|
11 Jun 1987
|
T-PA Approved in France
|
|
29 May 1987
|
FDA Committee Reviews Activase t-PA
|
|
24 Apr 1987
|
Genentech Reports First Quarter Results
|
|
01 Apr 1987
|
FDA Cardiorenal Advisory Committee to Review t-PA
|
|
12 Mar 1987
|
Genentech Completes Sale of $150 Million Convertable Subordonated Debentures in Europe
|
|
06 Mar 1987
|
Genentech Files Lawsuit Against FDA for Legalization of Orphan Drug Standards for Human Growth Hormone
|
|
21 Jan 1987
|
Genentech Reports Substantial Increase in 1986 Financial Results
|
|
19 Jan 1987
|
Progress on Genentech t-PA Patent Application in Japan
|
|
05 Jan 1987
|
Genentech Completes Early Buyout Or First Two R&D Partnerships
|
|
30 Dec 1986
|
Genentech Partnership Purchases Recieve Majority Approval
|
|
15 Dec 1986
|
Genentech Names Chief Financial Officer
|
|
27 Oct 1986
|
Genentech Proposes Early Partnership Buyout
|
|
16 Oct 1986
|
Genentech Reports Third Quarter Results
|
|
12 Sep 1986
|
Genentech To Defend Patent Suit
|
|
04 Aug 1986
|
Genentech Elects New Director to Its Board
|
|
04 Aug 1986
|
Genentech Names Four Vice Presidents
|
|
23 Jul 1986
|
Genentech Reports Second Quarter Results
|
|
25 Apr 1986
|
Genentech Reports First Quarter Results
|
|
26 Feb 1986
|
Genentech's T-PA Patent Issues in the United Kingdom Today Suit Against Wellcome Follow
|
|
12 Feb 1986
|
Genentech Reports Substantial Increase in 1985 Revenues and Income
|
|
21 Jan 1986
|
Genentech Announces 2 For 1 Stock Split
|
|
17 Dec 1985
|
Genentech Awarded Orphan Drug Status For Growth Hormone
|
|
12 Nov 1985
|
Business Venture Formed for Vitamin C Process Development
|
|
24 Oct 1985
|
Genentech Reports Third Quarter Results
|
|
18 Oct 1985
|
FDA Approves Genentech's Drug to Treat Children's Growth Disorder
|
|
30 Jul 1985
|
Genentech Reports Second Quarter Results
|
|
16 Jul 1985
|
Recombinant DNA Technology
|
|
14 Jun 1985
|
Genentech and Major European Pharmaceutical Firm Announce Institute for Cancer Research
|
|
24 Apr 1985
|
Genentech Reports First Quarter Results
|
|
22 Apr 1985
|
Genentechs Answer to Pituitary Derived Growth Hormone: Recombinant DNA Technology
|
|
26 Mar 1985
|
Susan Atkins Joins Genentech
|
|
21 Mar 1985
|
Genentech Forms Canadian Marketing Joint Venture With Major Pharmaceutical Company
|
|
15 Mar 1985
|
Genentech Offers 1 Million Of Common Stock At $45 Per Share
|
|
28 Feb 1985
|
Genentech Plans To File For Public Offering
|
|
14 Feb 1985
|
Genentech Reports Substantial Increase in 1984 Revenues and Income
|
|
14 Jan 1985
|
Media Advisory
|
|
02 Jan 1985
|
Genentech Clinical Partners III Raises $30.7 Million For The Development Of TNF
|
|
30 Oct 1984
|
Genentech Reports Third Quarter Results
|
|
14 Sep 1984
|
Genentech Reports on Meeting with FDA Advisory Committee
|
|
11 Sep 1984
|
Cutter To Receive Factor VIII License From Genentech
|
|
19 Jul 1984
|
Genentech, Inc. Reports Second Quarter Results
|
|
06 Jun 1984
|
Promising New Anti-Cancer Drug Produced By Genentech
|
|
23 Apr 1984
|
Genentech Expands Its Patent Department
|
|
19 Apr 1984
|
Genentech Reports First Quarter Results
|
|
13 Mar 1984
|
King of Sweden Presents Genentech President with Membership in Royal Swedish Academy
|
|
21 Feb 1984
|
Genentech Has Begun Human Evaluation of t-PA in Heart Attack Victims
|
|
15 Feb 1984
|
Genentech Reports Significant Increase in 1983 Revenues and Income
|
|
10 Jan 1984
|
Genentech President Gives Stock Analysts Preview Of 1983 Results and Beyond
|
|
05 Jan 1984
|
Travenol And Genentech Sign Definitive Agreement To Form Diagnostics Joint Venture
|
|
20 Dec 1983
|
Genentech Begins Human Evaluation of Human Gamma Interferon
|
|
15 Dec 1983
|
Genentech and Major European Pharmaceutical Firm Announce Commercialization Agreement on T-PA
|
|
01 Dec 1983
|
Travenol and Genentech to Form Diagnostics Joint Venture
|
|
14 Nov 1983
|
Dr. Goeddel Of Genentech Receives Prestigious Eli Lilly Award
|
|
10 Nov 1983
|
Media Advisory
|
|
20 Oct 1983
|
Genentech Reports Third Quarter Results
|
|
19 Aug 1983
|
Genentech, Inc. and Granada Announce bovine interferon R&D Agreement
|
|
09 Aug 1983
|
Genentech Reports Second Quarter Results
|
|
22 Jul 1983
|
Hewlett-Packard and Genentech Form Joint Venture
|
|
29 Jun 1983
|
Genentech Clinical Partners II Raises $34 Million for The Development of t-PA
|
|
24 May 1983
|
Possible Collaboration Between Genentech And Hewlett-Packard
|
|
10 May 1983
|
Genentech Obtains Exclusive Development Rights on T-PA
|
|
05 May 1983
|
Genentech Appoints Four Vice Presidents
|
|
29 Apr 1983
|
Genetech Plans to Form New R&D Partnership for TPA Development
|
|
29 Apr 1983
|
Genentech Reports First Quarter Results
|
|
17 Feb 1983
|
Genentech 1982 Revenues and Net Income Up; Company Announces 3 For 2 Stock Split
|
|
02 Nov 1982
|
Genentech Reports Third Quarter Results
|
|
29 Oct 1982
|
First Recombinant DNA Product Approved By The Food And Drug Administration
|
|
22 Oct 1982
|
Genentech Elects Two New Directors to Its Board
|
|
20 Oct 1982
|
Swedish Group Invests $20 Million in Genentech
|
|
19 Oct 1982
|
Genentech Plans to Meet Year-End Goals Despite a Third Quarter Loss
|
|
13 Oct 1982
|
Genentech Establishes New Research Partnership
|
|
16 Sep 1982
|
Geneticist Martin To Join Genentech as Vice President of Research
|
|
27 Aug 1982
|
Genentech Announces New Vice-President
|
|
25 Aug 1982
|
Genentech Announces Possible Research And Development Partnership
|
|
27 Jul 1982
|
Genentech Reports Second Quarter Results
|
|
23 Jul 1982
|
(TPA) Produced By Recombinant DNA Techniques
|
|
22 Jun 1982
|
Genentech, Inc. Contracts With Two Japanese Companies to Develop New Thrombolytic Agent
|
|
17 May 1982
|
Mitsubishi Chemical Industries, Ltd. And Genentech, Inc. To Develop Human Albumin For Commercial Production
|
|
29 Apr 1982
|
Genentech, Inc. Reports Results For First Quarter, 1982
|
|
13 Apr 1982
|
Corning Glass, Genentech to Form Industrial Enzyme Company
|
|
08 Mar 1982
|
Genentech Scientists Develop Bovine Interferon
|
|
18 Feb 1982
|
Genentech Revenues Up 137% Net Income Up Slightly
|
|
06 Jan 1982
|
Genentech Acquires Site For Future Facilities Expansion in South San Francisco
|
|
24 Nov 1981
|
Human Serum Albumin Produced By Recombinant DNA
|
|
31 Oct 1981
|
Genentech, Inc. Reports Third Quarterly Results
|
|
30 Oct 1981
|
Five Genentech Products Receive NIH Approval for Large Scale Production
|
|
22 Oct 1981
|
The first successful expression of immune interferon by recombinant DNA
|
|
21 Oct 1981
|
David Packard Elected to Board of Directors of Genentech
|
|
29 Sep 1981
|
Genentech is Beginning Efficacy Studies with Human Growth Hormone in Children with Hypopituitarism
|
|
21 Sep 1981
|
First Major Investment by Japanese Interests in Genentech
|
|
03 Aug 1981
|
Genentech, Inc. Reports Second Quarter Results
|
|
01 May 1981
|
Genentech, Inc., Reports First Quarter Revenues of $3.9 Million in 1981 vs. $1.6 Million in 1980
|
|
18 Feb 1981
|
Genentech Reports Annual Revenues of $9.0 Million in 1980 Vs. $3.4 Million in 1979
|
|
12 Jan 1981
|
FDA-Approved Clinical Tests on Humans Begin Today With Human Growth Hormone Made by Recombinant DNA
|
|
08 Jan 1981
|
Flour Purchases Shares in Genentech
|
|
19 Aug 1980
|
Genentech Files Registration Statement With SEC For Its Initial Public Offering
|
|
04 Jun 1980
|
Genentech Announces Successful Production and Preliminary Biological Tests For Fibroblast and Leukocyte Interferon
|
|
01 Jan 1980
|
Supreme Court Decision Will Spur Genetics Industry
|
|
11 Jul 1979
|
First Successful Bacterial Production of Human Growth Hormone Announced
|
|
06 Sep 1978
|
First Successful Laboratory Production of Human Insulin Announced
|
